<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxins (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Toxins (Basel)</journal-id><journal-id journal-id-type="publisher-id">toxins</journal-id><journal-title-group><journal-title>Toxins</journal-title></journal-title-group><issn pub-type="epub">2072-6651</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998104</article-id><article-id pub-id-type="pmc">PMC11860698</article-id>
<article-id pub-id-type="doi">10.3390/toxins17020087</article-id><article-id pub-id-type="publisher-id">toxins-17-00087</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Rattlesnake Roundup: Point-of-Care Thrombelastographic Methods Define the Molecular Impacts on Coagulation of <italic toggle="yes">Crotalus</italic> Venom Toxins In Vitro and In Vivo</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8072-9883</contrib-id><name><surname>Nielsen</surname><given-names>Vance G.</given-names></name></contrib></contrib-group><aff id="af1-toxins-17-00087">Department of Anesthesiology, College of Medicine, University of Arizona, Tucson, AZ 85750, USA; <email>vnielsen@anesth.arizona.edu</email></aff><pub-date pub-type="epub"><day>13</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>87</elocation-id><history><date date-type="received"><day>17</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>11</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the author.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>A malalignment between rattlesnake-envenomed patients&#x02019; degree of compromised coagulation and the data generated by standard hematological determinations generated with blood samples anticoagulated with calcium (Ca) chelating agents is almost certain. Many rattlesnake venom toxins are Ca-independent toxins that likely continue to damage plasmatic and cellular components of coagulation in blood samples (anticoagulated with Ca chelation) during transportation from the emergency department to the clinical laboratory. The most straightforward approach to abrogate this patient&#x02013;laboratory malalignment is to reduce &#x0201c;needle to activation time&#x0201d;&#x02014;the time from blood collection to commencement of laboratory analysis&#x02014;with utilization of point-of-care (POC) technology such as thrombelastography. The workflow and history of standard and POC approaches to hematological assessment is reviewed. Further, using a preclinical model of envenomation with four different rattlesnake venoms, the remarkably diverse damage to coagulation revealed with POC thrombelastography is presented. It is anticipated that future investigation and potential changes in clinical monitoring practices with POC methods of hematological assessment will improve the management of envenomed patients and assist in precision care.</p></abstract><kwd-group><kwd>rattlesnake venom</kwd><kwd>serine protease</kwd><kwd>metalloproteinase</kwd><kwd>fibrinogen concentration</kwd><kwd>platelet count</kwd><kwd>thrombelastography</kwd><kwd>rabbit model</kwd><kwd>point-of-care methods</kwd></kwd-group><funding-group><award-group><funding-source>Flinn Foundation</funding-source><award-id>22-06454</award-id></award-group><funding-statement>This research was funded by the Flinn Foundation, 1802 N. Central Avenue, Phoenix, Arizona 85004, USA. The grant is entitled &#x0201c;Ruthenium-Based Antivenom Development&#x0201d;, with the grant number being #22-06454.</funding-statement></funding-group></article-meta><notes notes-type="Key Contribution"><title>Key Contribution</title><p>The malalignment of envenomed patients&#x02019; coagulation status and standard hematological assessments secondary to variability in venom toxins (e.g., Ca-independent toxins) is presented, using recent works involving North American rattlesnakes as the backdrop.</p></notes></front><body><sec sec-type="intro" id="sec1-toxins-17-00087"><title>1. Introduction</title><p>The field of rattlesnake envenomation can be a kaleidoscope of clinical, preclinical, and molecular bodies of information that can align or conflict with each other [<xref rid="B1-toxins-17-00087" ref-type="bibr">1</xref>,<xref rid="B2-toxins-17-00087" ref-type="bibr">2</xref>,<xref rid="B3-toxins-17-00087" ref-type="bibr">3</xref>,<xref rid="B4-toxins-17-00087" ref-type="bibr">4</xref>,<xref rid="B5-toxins-17-00087" ref-type="bibr">5</xref>,<xref rid="B6-toxins-17-00087" ref-type="bibr">6</xref>,<xref rid="B7-toxins-17-00087" ref-type="bibr">7</xref>,<xref rid="B8-toxins-17-00087" ref-type="bibr">8</xref>,<xref rid="B9-toxins-17-00087" ref-type="bibr">9</xref>,<xref rid="B10-toxins-17-00087" ref-type="bibr">10</xref>,<xref rid="B11-toxins-17-00087" ref-type="bibr">11</xref>,<xref rid="B12-toxins-17-00087" ref-type="bibr">12</xref>,<xref rid="B13-toxins-17-00087" ref-type="bibr">13</xref>,<xref rid="B14-toxins-17-00087" ref-type="bibr">14</xref>,<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>,<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>,<xref rid="B17-toxins-17-00087" ref-type="bibr">17</xref>,<xref rid="B18-toxins-17-00087" ref-type="bibr">18</xref>,<xref rid="B19-toxins-17-00087" ref-type="bibr">19</xref>,<xref rid="B20-toxins-17-00087" ref-type="bibr">20</xref>,<xref rid="B21-toxins-17-00087" ref-type="bibr">21</xref>,<xref rid="B22-toxins-17-00087" ref-type="bibr">22</xref>,<xref rid="B23-toxins-17-00087" ref-type="bibr">23</xref>,<xref rid="B24-toxins-17-00087" ref-type="bibr">24</xref>,<xref rid="B25-toxins-17-00087" ref-type="bibr">25</xref>,<xref rid="B26-toxins-17-00087" ref-type="bibr">26</xref>,<xref rid="B27-toxins-17-00087" ref-type="bibr">27</xref>,<xref rid="B28-toxins-17-00087" ref-type="bibr">28</xref>,<xref rid="B29-toxins-17-00087" ref-type="bibr">29</xref>,<xref rid="B30-toxins-17-00087" ref-type="bibr">30</xref>,<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>,<xref rid="B32-toxins-17-00087" ref-type="bibr">32</xref>,<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B34-toxins-17-00087" ref-type="bibr">34</xref>,<xref rid="B35-toxins-17-00087" ref-type="bibr">35</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B37-toxins-17-00087" ref-type="bibr">37</xref>,<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>,<xref rid="B40-toxins-17-00087" ref-type="bibr">40</xref>,<xref rid="B41-toxins-17-00087" ref-type="bibr">41</xref>,<xref rid="B42-toxins-17-00087" ref-type="bibr">42</xref>,<xref rid="B43-toxins-17-00087" ref-type="bibr">43</xref>,<xref rid="B44-toxins-17-00087" ref-type="bibr">44</xref>,<xref rid="B45-toxins-17-00087" ref-type="bibr">45</xref>,<xref rid="B46-toxins-17-00087" ref-type="bibr">46</xref>,<xref rid="B47-toxins-17-00087" ref-type="bibr">47</xref>]. Rattlesnake venom is complex, containing metalloproteinases (SVMPs), serine proteases (SVSPs), thrombin-like enzymes (SVTLEs), phospholipaseA<sub>2</sub> (SVPLA<sub>2</sub>), extracellular vesicles, and nonenzymatic compounds such as c-type lectins and disintegrins [<xref rid="B1-toxins-17-00087" ref-type="bibr">1</xref>,<xref rid="B2-toxins-17-00087" ref-type="bibr">2</xref>,<xref rid="B3-toxins-17-00087" ref-type="bibr">3</xref>,<xref rid="B20-toxins-17-00087" ref-type="bibr">20</xref>,<xref rid="B21-toxins-17-00087" ref-type="bibr">21</xref>,<xref rid="B22-toxins-17-00087" ref-type="bibr">22</xref>,<xref rid="B23-toxins-17-00087" ref-type="bibr">23</xref>,<xref rid="B24-toxins-17-00087" ref-type="bibr">24</xref>,<xref rid="B25-toxins-17-00087" ref-type="bibr">25</xref>,<xref rid="B27-toxins-17-00087" ref-type="bibr">27</xref>,<xref rid="B28-toxins-17-00087" ref-type="bibr">28</xref>,<xref rid="B29-toxins-17-00087" ref-type="bibr">29</xref>,<xref rid="B30-toxins-17-00087" ref-type="bibr">30</xref>]. In addition to vast diversity in molecular target, these compounds within rattlesnake venom also have variability in biochemical requirements to be biologically active, such as being calcium (Ca)-independent [<xref rid="B1-toxins-17-00087" ref-type="bibr">1</xref>,<xref rid="B2-toxins-17-00087" ref-type="bibr">2</xref>,<xref rid="B3-toxins-17-00087" ref-type="bibr">3</xref>,<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>] or Ca-dependent [<xref rid="B1-toxins-17-00087" ref-type="bibr">1</xref>,<xref rid="B2-toxins-17-00087" ref-type="bibr">2</xref>,<xref rid="B3-toxins-17-00087" ref-type="bibr">3</xref>,<xref rid="B34-toxins-17-00087" ref-type="bibr">34</xref>,<xref rid="B35-toxins-17-00087" ref-type="bibr">35</xref>,<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>]. This diversity in venom proteome has significant implications for not just the clinical outcomes associated with rattlesnake envenomation but also markedly impacts the laboratory monitoring, antivenom administration, and experimental designs with in vitro and in vivo models. While the diagnosis and treatment of rattlesnake envenomation is based on clinical symptoms such as pain, edema and ecchymosis at the bite site, and the speed of spread of such tissue damage [<xref rid="B47-toxins-17-00087" ref-type="bibr">47</xref>], the use of clinical hematological laboratory assessments (e.g., fibrinogen concentration, platelet count) are routinely made [<xref rid="B4-toxins-17-00087" ref-type="bibr">4</xref>,<xref rid="B5-toxins-17-00087" ref-type="bibr">5</xref>,<xref rid="B6-toxins-17-00087" ref-type="bibr">6</xref>,<xref rid="B7-toxins-17-00087" ref-type="bibr">7</xref>,<xref rid="B8-toxins-17-00087" ref-type="bibr">8</xref>,<xref rid="B9-toxins-17-00087" ref-type="bibr">9</xref>,<xref rid="B10-toxins-17-00087" ref-type="bibr">10</xref>,<xref rid="B11-toxins-17-00087" ref-type="bibr">11</xref>,<xref rid="B12-toxins-17-00087" ref-type="bibr">12</xref>,<xref rid="B13-toxins-17-00087" ref-type="bibr">13</xref>,<xref rid="B14-toxins-17-00087" ref-type="bibr">14</xref>,<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>,<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>,<xref rid="B17-toxins-17-00087" ref-type="bibr">17</xref>,<xref rid="B18-toxins-17-00087" ref-type="bibr">18</xref>,<xref rid="B19-toxins-17-00087" ref-type="bibr">19</xref>]. The severity of envenomation is often assessed by the degree of derangement of the laboratory values, with reports of no fibrinogen [<xref rid="B12-toxins-17-00087" ref-type="bibr">12</xref>,<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>] detected or marked thrombocytopenia noted [<xref rid="B5-toxins-17-00087" ref-type="bibr">5</xref>,<xref rid="B6-toxins-17-00087" ref-type="bibr">6</xref>,<xref rid="B7-toxins-17-00087" ref-type="bibr">7</xref>,<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>]. Persistent or recurrent derangements of coagulation are also commonly reported with standard hematological methods [<xref rid="B5-toxins-17-00087" ref-type="bibr">5</xref>,<xref rid="B18-toxins-17-00087" ref-type="bibr">18</xref>,<xref rid="B19-toxins-17-00087" ref-type="bibr">19</xref>]. While these investigations provide in detail the clinical laboratories used to assess the severity of envenomation, to determine the degree of laboratory-based coagulopathy, and to measure the efficacy of antivenom administration [<xref rid="B4-toxins-17-00087" ref-type="bibr">4</xref>,<xref rid="B5-toxins-17-00087" ref-type="bibr">5</xref>,<xref rid="B6-toxins-17-00087" ref-type="bibr">6</xref>,<xref rid="B7-toxins-17-00087" ref-type="bibr">7</xref>,<xref rid="B8-toxins-17-00087" ref-type="bibr">8</xref>,<xref rid="B9-toxins-17-00087" ref-type="bibr">9</xref>,<xref rid="B10-toxins-17-00087" ref-type="bibr">10</xref>,<xref rid="B11-toxins-17-00087" ref-type="bibr">11</xref>,<xref rid="B12-toxins-17-00087" ref-type="bibr">12</xref>,<xref rid="B13-toxins-17-00087" ref-type="bibr">13</xref>,<xref rid="B14-toxins-17-00087" ref-type="bibr">14</xref>,<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>,<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>,<xref rid="B17-toxins-17-00087" ref-type="bibr">17</xref>,<xref rid="B18-toxins-17-00087" ref-type="bibr">18</xref>,<xref rid="B19-toxins-17-00087" ref-type="bibr">19</xref>], key details that are the underpinning of the biological relevance of the laboratory values generated are missing. There are marked degrees of uncertainty caused by the interplay of snake venom toxins, blood sample collection, and hematological methodology that disengage laboratory results from patient condition that have been completely unappreciated. One of the goals of this review is to raise awareness of this problem and introduce the concept of &#x0201c;needle to activation&#x0201d; as a new goal for both clinicians and laboratorians that treat and investigation envenomation, respectively. The reduction of time from blood sample collection to the activation of blood sample within a hematological parameter measuring device is the new challenge, with the use of point-of-care (POC) viscoelastic methods at the forefront of this endeavor. The other goal of this review is to demonstrate how this approach to coagulation assessment has been used in a preclinical, rabbit model of envenomation in the recent past utilizing venom from the North American rattlesnakes <italic toggle="yes">Crotalus atrox</italic> (<italic toggle="yes">C. atrox</italic>, Western diamondback rattlesnake), <italic toggle="yes">C. scutulatus scutulatus</italic> (<italic toggle="yes">C. s. scutulatus</italic>, Mojave rattlesnake, venom type B), and <italic toggle="yes">C. adamanteus</italic> (Eastern diamondback rattlesnake) [<xref rid="B32-toxins-17-00087" ref-type="bibr">32</xref>,<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>]. Further, there will be the inclusion of previously unpublished data utilizing venom derived from <italic toggle="yes">C. molossus molossus</italic> (<italic toggle="yes">C. m. molossus</italic>, Northern blacktail rattlesnake). But, first, the reader should consider the problem posed by rattlesnake-envenomed patients without much clinical bleeding found to have laboratory values that are &#x0201c;bleeding to death&#x0201d;.</p></sec><sec id="sec2-toxins-17-00087"><title>2. Swollen Patients, Bleeding Test Tubes</title><p>While there are always patients with clinical signs of envenomation that include edema and bleeding at the bite site, the assessment of the degree of compromise of coagulation is subject to uncertainty and variability, as will be subsequently presented. First, understanding the methodology involved in blood collection and standard hematological analyses needs to be considered. Specifically, whole-blood samples collected from patients are usually placed into a &#x0201c;blue top&#x0201d;, sodium (Na) citrate-containing tube for determination of activated partial thromboplastin time (aPTT), prothrombin time (PT), and fibrinogen concentration. Further, whole blood is also placed into a &#x0201c;purple top&#x0201d;, ethylenediaminetetraacetic acid-containing (EDTA) tube for assessment of platelet count. Both tubes are designed to prevent contact protein, factor XII-mediated thrombin generation via interactions of blood with the plastic surface of the tube by chelating Ca with Na citrate or EDTA, which prevents calcium-dependent prothrombin to thrombin conversion. This chelation allows sufficient time for transportation of the sample to the clinical laboratory. Additional centrifugation is required for Na citrate anticoagulated samples before analyses, whereas samples with EDTA may be analyzed upon arrival to the laboratory, as seen in <xref rid="toxins-17-00087-f001" ref-type="fig">Figure 1</xref>.</p><p>This methodology is simple and highly reliable when assessing the laboratory parameters displayed when evaluating patients with potential deficits in coagulation caused by most congenital and acquired hematological diseases. However, there is one tacit assumption made when considering these standard laboratory tests: chelation of Ca by Na citrate and EDTA quenches all hematological processes before the final analyses. And, for most clinically encountered scenarios, this approach is highly reliable when assessing patients. In fact, many in the readership may consider the use of Na citrate and EDTA the &#x0201c;gold standard&#x0201d; because of presumed stability of the sample. However, when it comes to venomous snakebite, there is a very serious problem with this method of hematological assessment that is subsequently presented.</p><p>Snake venom compounds, enzymatic and nonenzymatic, have activities and interactions with target molecules such as fibrinogen and platelet receptors that may be Ca-dependent or Ca-independent [<xref rid="B1-toxins-17-00087" ref-type="bibr">1</xref>,<xref rid="B22-toxins-17-00087" ref-type="bibr">22</xref>,<xref rid="B23-toxins-17-00087" ref-type="bibr">23</xref>,<xref rid="B24-toxins-17-00087" ref-type="bibr">24</xref>,<xref rid="B25-toxins-17-00087" ref-type="bibr">25</xref>,<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>,<xref rid="B34-toxins-17-00087" ref-type="bibr">34</xref>,<xref rid="B35-toxins-17-00087" ref-type="bibr">35</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B37-toxins-17-00087" ref-type="bibr">37</xref>,<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. That means snake venom within the blood collected from a snake bite victim may or may not be destroying coagulation proteins in the Na citrate anticoagulated sample or aggregating (or preventing future aggregation) of platelets in the EDTA anticoagulated sample. Thus, depending on the variability in time for each process prior to analysis depicted in <xref rid="toxins-17-00087-f001" ref-type="fig">Figure 1</xref>, a coagulopathy may be created within the blood samples that clearly does not reflect what is occurring within the patient. This is not to say that the envenomed patient does not have compromised coagulation for clinical reasons, such as severe envenomation or delayed presentation (e.g., 16 h after envenomation [<xref rid="B4-toxins-17-00087" ref-type="bibr">4</xref>]) prior to antivenom administration. Instead, the use of Ca chelation as a method of preservation of coagulation prior to transportation and processing/analyses remote from the area of patient treatment adds a degree of uncertainty to the alignment of the patient clinical situation with the laboratory analysis.</p><p>The most unambiguous demonstration of the degradation of coagulation in Na citrate anticoagulated human plasma by rattlesnake venom, in this instance obtained from <italic toggle="yes">C. atrox</italic>, is observed in [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>], a publication nearly nine years old. On page 507, in <xref rid="toxins-17-00087-f001" ref-type="fig">Figure 1</xref>, it is observed that five minutes of exposure of Na citrated anticoagulated human plasma to 0.5 &#x000b5;g of venom resulted in significant degradation of coagulation as assessed by thrombelastography [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>]. Further, and critically, exposure to the same concentration of venom for twenty minutes all but eliminated coagulation, as displayed on page 508, <xref rid="toxins-17-00087-f002" ref-type="fig">Figure 2</xref> [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>]. While these samples were exposed to a temperature of 37 &#x000b0;C [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>], which is greater than room temperature, during transport from the bedside to the laboratory, it is highly likely that degradation of the sample by Ca-independent enzymes would occur after envenomation by this viper, as displayed in <xref rid="toxins-17-00087-f001" ref-type="fig">Figure 1</xref> of this work. These data, using human plasma anticoagulated with Na citrate, serve as perhaps the strongest rationale to advocate for POC methods to assess coagulation at the bedside.</p><p>The same problem of in vitro compromise of coagulation by Ca-independent venom proteins presents itself in a reverse manner when antivenom is administered. Fibrinogen concentrations and platelet counts may rapidly recover after envenomed patients are treated, sometimes improving markedly with repeated administrations of antivenom [<xref rid="B5-toxins-17-00087" ref-type="bibr">5</xref>,<xref rid="B6-toxins-17-00087" ref-type="bibr">6</xref>,<xref rid="B7-toxins-17-00087" ref-type="bibr">7</xref>,<xref rid="B10-toxins-17-00087" ref-type="bibr">10</xref>,<xref rid="B12-toxins-17-00087" ref-type="bibr">12</xref>,<xref rid="B14-toxins-17-00087" ref-type="bibr">14</xref>,<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>,<xref rid="B17-toxins-17-00087" ref-type="bibr">17</xref>,<xref rid="B18-toxins-17-00087" ref-type="bibr">18</xref>,<xref rid="B19-toxins-17-00087" ref-type="bibr">19</xref>]. Standard antivenom (e.g., intravenous, antibody-based) administration removes circulating venom, and thus there is less venom to compromise coagulation in the patient&#x02019;s circulation and in their blood samples. Eventually, the effects of venom are abrogated when adequate antivenom is administered, and then&#x02014;and only then&#x02014;the in vitro standard hematological laboratory assessments are representative of the patient&#x02019;s in vivo coagulation. This malalignment could lead to potential excessive antivenom administration or even unneeded transfusion of platelets/fresh frozen plasma/cryoprecipitate to treat a clinical coagulopathy that does not exist. So how does one eliminate or at least significantly diminish the divergence in the clinical state of the patient from compromised laboratory analyses following a venomous snake bite? A potential solution has been in plain sight for decades [<xref rid="B48-toxins-17-00087" ref-type="bibr">48</xref>].</p></sec><sec id="sec3-toxins-17-00087"><title>3. Reducing &#x0201c;Needle to Activation Time&#x0201d;</title><p>The simplest approach to aligning in vivo coagulopathy to laboratory hematological assessment is decreasing the time from blood collection to commencement of the laboratory test. This is one of the goals of POC evaluation, and a typical laboratory workflow diagram that illustrates the basic events and devices with a thrombelastographic system is displayed in <xref rid="toxins-17-00087-f002" ref-type="fig">Figure 2</xref>.</p><p>The first cases of POC thrombelastographic analysis with &#x0201c;native whole blood&#x0201d; (meaning without processing or activation) were reported in 1990, involving patients bitten by <italic toggle="yes">Dispholidus typus</italic> (Boomslang) in South Africa [<xref rid="B48-toxins-17-00087" ref-type="bibr">48</xref>]. Native whole blood must be collected and placed into a thrombelastograph within 5 min or less to prevent activation of coagulation within the syringe used to collect the sample. Standard hematological assessments were also made, and, given that both patients presented with severe clinical bleeding 36 h after envenomation, both standard hematological tests and thrombelastographic data demonstrated severe loss of coagulation capacity by every measure made [<xref rid="B48-toxins-17-00087" ref-type="bibr">48</xref>]. This is the first description of this approach, and it is of interest that <italic toggle="yes">D. typus</italic> venom activity is procoagulant, activating prothrombin [<xref rid="B49-toxins-17-00087" ref-type="bibr">49</xref>,<xref rid="B50-toxins-17-00087" ref-type="bibr">50</xref>], and is Ca-independent [<xref rid="B50-toxins-17-00087" ref-type="bibr">50</xref>]. There is an earlier report of using thrombelastography to assess the effects of envenomation by a <italic toggle="yes">Trimeresurus</italic> species, but this report involved using blood that was anticoagulated with Na citrate that then had Ca added to commence data collection [<xref rid="B51-toxins-17-00087" ref-type="bibr">51</xref>]. A year later, it was reported that similar <italic toggle="yes">Trimeresurus</italic> species had anticoagulant venom that was Ca-dependent [<xref rid="B52-toxins-17-00087" ref-type="bibr">52</xref>], which was later observed utilizing similar <italic toggle="yes">Trimeresurus</italic> venoms with thrombelastography with human plasma [<xref rid="B53-toxins-17-00087" ref-type="bibr">53</xref>]. Considered together, the first description of thrombelastographic assessment of envenomation was likely in alignment with the patient&#x02019;s conditions, as the activity of the venom involved was Ca-dependent and therefore not interacting with the Na citrate anticoagulated blood sample prior to analysis [<xref rid="B51-toxins-17-00087" ref-type="bibr">51</xref>]. In contrast, POC thrombelastographic analysis was quintessential to being aligned with the patient&#x02019;s condition, given the Ca-independent activity of <italic toggle="yes">D. typus</italic> venom [<xref rid="B48-toxins-17-00087" ref-type="bibr">48</xref>]. In summary, if the Ca-dependent status of the venom activity derived from a snake bite is unknown, then the approach most likely to result in data in alignment with the victim&#x02019;s state of coagulation would be derived from POC thrombelastographic methods, such as has been used in numerous laboratory and preclinical investigations in recent years [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>,<xref rid="B32-toxins-17-00087" ref-type="bibr">32</xref>,<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B34-toxins-17-00087" ref-type="bibr">34</xref>,<xref rid="B35-toxins-17-00087" ref-type="bibr">35</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B37-toxins-17-00087" ref-type="bibr">37</xref>,<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. Put another way, a reduction in &#x0201c;needle to activation time&#x0201d; may be the key to success when assessing the impact of envenomation by North American rattlesnakes with markedly diverse venom characteristics [<xref rid="B4-toxins-17-00087" ref-type="bibr">4</xref>,<xref rid="B5-toxins-17-00087" ref-type="bibr">5</xref>,<xref rid="B6-toxins-17-00087" ref-type="bibr">6</xref>,<xref rid="B7-toxins-17-00087" ref-type="bibr">7</xref>,<xref rid="B8-toxins-17-00087" ref-type="bibr">8</xref>,<xref rid="B9-toxins-17-00087" ref-type="bibr">9</xref>,<xref rid="B10-toxins-17-00087" ref-type="bibr">10</xref>,<xref rid="B11-toxins-17-00087" ref-type="bibr">11</xref>,<xref rid="B12-toxins-17-00087" ref-type="bibr">12</xref>,<xref rid="B13-toxins-17-00087" ref-type="bibr">13</xref>,<xref rid="B14-toxins-17-00087" ref-type="bibr">14</xref>,<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>,<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>,<xref rid="B20-toxins-17-00087" ref-type="bibr">20</xref>,<xref rid="B21-toxins-17-00087" ref-type="bibr">21</xref>,<xref rid="B22-toxins-17-00087" ref-type="bibr">22</xref>,<xref rid="B23-toxins-17-00087" ref-type="bibr">23</xref>,<xref rid="B24-toxins-17-00087" ref-type="bibr">24</xref>,<xref rid="B25-toxins-17-00087" ref-type="bibr">25</xref>,<xref rid="B26-toxins-17-00087" ref-type="bibr">26</xref>,<xref rid="B27-toxins-17-00087" ref-type="bibr">27</xref>,<xref rid="B28-toxins-17-00087" ref-type="bibr">28</xref>,<xref rid="B29-toxins-17-00087" ref-type="bibr">29</xref>,<xref rid="B30-toxins-17-00087" ref-type="bibr">30</xref>,<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>,<xref rid="B32-toxins-17-00087" ref-type="bibr">32</xref>,<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B34-toxins-17-00087" ref-type="bibr">34</xref>,<xref rid="B35-toxins-17-00087" ref-type="bibr">35</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B37-toxins-17-00087" ref-type="bibr">37</xref>,<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>].</p></sec><sec id="sec4-toxins-17-00087"><title>4. A Rattle Is About the Only Feature North American Rattlesnakes Share</title><p>Rattlesnakes may have venom that is procoagulant, anticoagulant, platelet activating (causing aggregation), or platelet inactivating (preventing aggregation) in nature; this variability is markedly species-specific. For example, while toxicologists that treat bites from the Eastern diamondback rattlesnake found in the Southeastern United states would not have to worry about their patient having a clinical course like one bitten by a Western diamondback rattlesnake in Arizona, both venoms have Ca-independent activities confirmed with thrombelastography [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>,<xref rid="B37-toxins-17-00087" ref-type="bibr">37</xref>]. Worse yet, the hemotoxic venom activity of the Mojave rattlesnake is Ca-dependent [<xref rid="B34-toxins-17-00087" ref-type="bibr">34</xref>,<xref rid="B35-toxins-17-00087" ref-type="bibr">35</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>], and the Western diamondback rattlesnake, with Ca-independent activity, occupies the same territory in Arizona. The fibrinogenolytic activity of both Western diamondback rattlesnake and Mojave rattlesnake venoms compromise plasmatic coagulation in vitro and in vivo, but only the venom of the Western diamondback rattlesnake compromises platelet function as determined by thrombelastography [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>,<xref rid="B32-toxins-17-00087" ref-type="bibr">32</xref>,<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B34-toxins-17-00087" ref-type="bibr">34</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>]. Whole-blood coagulation is not compromised by Mojave rattlesnake venom, while plasmatic coagulation is significantly decreased [<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>], demonstrating that, while fibrinolytic enzymes damage the ability of fibrinogen to be polymerized by thrombin, the ability of platelets to bind fibrin polymers with glycoprotein IIb/IIIa receptors are not. In contrast, the venom of the Eastern diamondback rattlesnake contains a serine protease with thrombin-like activity that polymerizes fibrinogen as a weak clot, depleting the fibrinogen concentration available for thrombin polymerization [<xref rid="B37-toxins-17-00087" ref-type="bibr">37</xref>]. This results in a simultaneous decrease in whole-blood and platelet-inhibited blood coagulation kinetics in vivo, as demonstrated via thrombelastography in the rabbit [<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. The loss of fibrinogen decreases fibrin polymer formation, which, in turn, decreases binding of platelet glycoprotein IIb/IIIa receptors that results in a loss of whole-blood clot strength that is platelet-mediated with Eastern diamondback rattlesnake venom that does not contain any antiplatelet activity [<xref rid="B14-toxins-17-00087" ref-type="bibr">14</xref>,<xref rid="B28-toxins-17-00087" ref-type="bibr">28</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. Thus, the thrombelastographic profile of envenomation of rabbits by the Western diamondback rattlesnake or Eastern diamondback rattlesnake will be nearly identical but for completely different biochemical reasons [<xref rid="B32-toxins-17-00087" ref-type="bibr">32</xref>,<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. <xref rid="toxins-17-00087-f003" ref-type="fig">Figure 3</xref> depicts images of these three rattlesnakes, representative venom activities to the right of each viper, and then observed changes in coagulation kinetics and corresponding thrombelastographic parameters.</p><p>In conclusion, diversity in venom toxins, especially in Ca-dependent/independent activities, in the species of venomous snake that share the same geographical area and threaten the same human population serves as a rationale for using POC thrombelastographic methodology to assess coagulopathy. Finally, to add to the data presented generated from these three rattlesnakes, de novo data obtained with <italic toggle="yes">C. m. molossus</italic> venom will be presented. This viper shares the same territory in Arizona as the Western diamondback rattlesnake and the Mojave rattlesnake.</p></sec><sec id="sec5-toxins-17-00087"><title>5. <italic toggle="yes">C. m. molossus</italic></title><p><italic toggle="yes">C. m. molossus</italic> is a medium-sized, relatively docile rattlesnake that is purported to have a primarily hemotoxic venom that is &#x0201c;two-thirds&#x0201d; as potent at the western diamondback [<xref rid="B40-toxins-17-00087" ref-type="bibr">40</xref>,<xref rid="B41-toxins-17-00087" ref-type="bibr">41</xref>,<xref rid="B42-toxins-17-00087" ref-type="bibr">42</xref>]; however, this author has not been able to confirm this ratio of potency between the two species with any scientific reference. Instead, in an investigation using lethal dose 50% (LD<sub>50</sub>) in mice as the outcome, it was prospectively noted that <italic toggle="yes">C. atrox</italic> venom had an intravenous LD<sub>50</sub> value of 3.79 mg/kg, whereas <italic toggle="yes">C. m. molossus</italic> venom had an LD<sub>50</sub> value of 4.42 mg/kg [<xref rid="B54-toxins-17-00087" ref-type="bibr">54</xref>]. Further, these investigators noted other works had reported that <italic toggle="yes">C. atrox</italic> venom had an intravenous LD<sub>50</sub> value of 3.74 mg/kg, whereas <italic toggle="yes">C. m. molossus</italic> venom had an LD<sub>50</sub> value of 2.04 mg/kg [<xref rid="B54-toxins-17-00087" ref-type="bibr">54</xref>]. Based on the variation of murine LD<sub>50</sub> values, there did not seem to be that much difference between the two venoms. Further, and intriguingly, there have only been two case reports of envenomation by <italic toggle="yes">C. m. molossus</italic> [<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>,<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>], with the first documenting severe pain, swelling and ecchymosis of the bitten limb, and coagulopathy featuring thrombocytopenia and hypofibrinogenemia in two adult men (31 and 47 years old) that required significant antivenom administration and hospitalization for 7&#x02013;10 days [<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>]. This report also featured an in vitro study of the venom, with the authors verifying fibrinogenolytic activity and the ability to cause platelet aggregation [<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>]. In sharp contrast, a 12-year-old female bitten by an adult <italic toggle="yes">C. m. molossus</italic> demonstrated no changes in coagulation, instead exhibiting lower limb pain and edema that easily resolved with antivenom administration, resulting in discharge from the hospital in two days [<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>]. The rattlesnakes inflicting the bites were adults [<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>,<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>]. Considered as a whole, these investigations involving either murine LD<sub>50</sub> [<xref rid="B54-toxins-17-00087" ref-type="bibr">54</xref>] or clinical and laboratory outcomes [<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>,<xref rid="B16-toxins-17-00087" ref-type="bibr">16</xref>] potentially demonstrate variability in potency following envenomation by <italic toggle="yes">C. m. molossus</italic>, beyond just being two-thirds as potent as <italic toggle="yes">C. atrox</italic> [<xref rid="B40-toxins-17-00087" ref-type="bibr">40</xref>,<xref rid="B41-toxins-17-00087" ref-type="bibr">41</xref>,<xref rid="B42-toxins-17-00087" ref-type="bibr">42</xref>].</p><p>Adding to the paucity of data available concerning <italic toggle="yes">C. m. molossus</italic> are the few and relatively older biochemical investigations of its venom [<xref rid="B43-toxins-17-00087" ref-type="bibr">43</xref>,<xref rid="B44-toxins-17-00087" ref-type="bibr">44</xref>,<xref rid="B45-toxins-17-00087" ref-type="bibr">45</xref>,<xref rid="B46-toxins-17-00087" ref-type="bibr">46</xref>]. Two early works identified metalloproteinases within the venom which were named M4 [<xref rid="B43-toxins-17-00087" ref-type="bibr">43</xref>] and M5 [<xref rid="B44-toxins-17-00087" ref-type="bibr">44</xref>] that were found to cleave the A&#x003b1; and B&#x003b2; chains of fibrinogen and the &#x003b1; and &#x003b2; chains of fibrin. Later work isolated another fibrinogenolytic metalloproteinase, CMM4 [<xref rid="B45-toxins-17-00087" ref-type="bibr">45</xref>], from the venom, which was also found to be one of the most potent hemorrhagic enzymes identified. Hemorrhagins destroy basement membranes, allowing bleeding into envenomed tissues. Of particular interest, an investigation that assessed the variation in fibrinolytic- and complement-activating properties between venoms obtained from variable sizes of <italic toggle="yes">C. m. molossus</italic> vipers found that smaller snakes had far less potential hemotoxicity compared to larger specimens [<xref rid="B46-toxins-17-00087" ref-type="bibr">46</xref>]. It should also be noted that the only work addressing <italic toggle="yes">C. m. molossus venom</italic>-mediated effects on platelet aggregation was presented in the first case report [<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>], which did not provide any detailed biochemical characterization of the compounds responsible. The components of venom that affect platelet activity include nonenzymatic proteins such as disintegrins that prevent aggregation, as found in <italic toggle="yes">C. atrox</italic> venom [<xref rid="B22-toxins-17-00087" ref-type="bibr">22</xref>], or c-type lectins that cause aggregation [<xref rid="B3-toxins-17-00087" ref-type="bibr">3</xref>]. In summary, while some preliminary investigation has been performed addressing the mechanisms responsible for the hemotoxicity of <italic toggle="yes">C. m. molossus</italic> venom, critical gaps in knowledge remain.</p><p>Given this background, the goals of the present study were as follows: (1) to utilize a validated rabbit model of subcutaneous envenomation [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>] to characterize the effects of <italic toggle="yes">C. m. molossus</italic> venom on whole-blood coagulation, without and with platelet inhibition, and (2) to test the hypothesis that site-directed ruthenium-based antivenom administration could significantly attenuate the effects of <italic toggle="yes">C. m. molossus</italic> venom in rabbits. Ruthenium-based antivenom is a mixture of inorganic ruthenium-containing compounds in a mixture of organic and inorganic solvents that acts by binding key amino acid residues in several venom toxins&#x02014;the readership may obtain greater detail from [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. The source of venom, hemotoxic constituents, and likely affected thrombelastographic parameters are displayed in <xref rid="toxins-17-00087-f004" ref-type="fig">Figure 4</xref>.</p></sec><sec sec-type="results" id="sec6-toxins-17-00087"><title>6. Results</title><sec id="sec6dot1-toxins-17-00087"><title>6.1. General Observations</title><p>Heart rate (168&#x02013;242 beats/min average range) and arterial oxygen saturation (92&#x02013;100% average range) values observed for all the animals were within the normal ranges reported previously with this model with other venoms [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. The area of skin with venom injection had an area of ecchymosis (approximately 4&#x02013;6 cm by 2&#x02013;3 cm) that was oval in appearance. This ecchymosis developed over the hour of observation and did not appear to bother the rabbit, likely secondary to the local anesthetic administered prior to venom injection. The one rabbit that was administered ruthenium-based antivenom had a very pale ecchymotic area with a thin, much darker border (1&#x02013;2 mm).</p></sec><sec id="sec6dot2-toxins-17-00087"><title>6.2. Dose&#x02013;Response of C. m. molossus Envenomation on Whole-Blood Coagulation</title><p>Administration of 4, 12, 18, or 24 mg/kg of <italic toggle="yes">C. m. molossus</italic> venom subcutaneously did not change coagulation in this model (n = 1 per dose). However, 40 mg/kg seemed to affect coagulation; thus, it was found that envenomation to this degree (n = 6) resulted in significantly increased whole-blood TMRTG values (58%) and decreased whole-blood MRTG values (35%) and TTG values (17%) one hour after envenomation, as seen in <xref rid="toxins-17-00087-f005" ref-type="fig">Figure 5</xref>. Based on the similar decrease in whole-blood coagulation, <italic toggle="yes">C. m. molossus</italic> venom is ten-fold less potent than <italic toggle="yes">C. atrox</italic> venom [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>]. Platelet-inhibited samples demonstrated a significant increase in TMRTG values (31%) and a significant decrease in MRTG values (33%); however, there was no significant change in TTG values, as noted in <xref rid="toxins-17-00087-f005" ref-type="fig">Figure 5</xref>. Critically, the %TTG<sub>Platelet</sub> value decreased significantly from 86.1 &#x000b1; 1.6% to 84.1 &#x000b1; 2.1%.</p><p>Unfortunately, given the ten-fold greater amount of venom required to conduct these experiments than was anticipated by the author, there was only enough venom remaining for one animal experiment with antivenom administration and for in vitro investigation, subsequently described. The author viewed the in vivo experiment with ambivalence, as the concentration and quantity of the ruthenium-based antivenom permitted to be administered to rabbits of this weight class would likely be inadequate to neutralize the largest dose of venom ever administered in this model. Nevertheless, in the hope of obtaining insight, the experiment was conducted, with the results displayed in <xref rid="toxins-17-00087-t001" ref-type="table">Table 1</xref>.</p><p>Administration of the ruthenium-based antivenom resulted in whole-blood samples that had TMRTG values that increased 29%, MRTG values that did not change, TTG values that increased 0.9%, and %TTG<sub>Platelet</sub> that decreased by 0.2%. These changes were far less than that observed in whole blood obtained from rabbits not administered antivenom in <xref rid="toxins-17-00087-f005" ref-type="fig">Figure 5</xref>. The platelet-inhibited samples of this animal demonstrated an increase in TMRTG values (25%), a decrease in MRTG values (34%), and an increase in TTG (2%). These changes were not very different from those observed in animals not administered antivenom in <xref rid="toxins-17-00087-f005" ref-type="fig">Figure 5</xref>. Thus, under these circumstances, it appeared that ruthenium-based antivenom attenuated the effects of venom on platelet strength but did not modify the effects on plasmatic coagulation.</p></sec><sec id="sec6dot3-toxins-17-00087"><title>6.3. Effects on C. m. molossus Venom on Human Plasmatic Coagulation and Attenuation of Venom Effects by RuCl<sub>3</sub></title><p>The rationale for this series of experiments was to determine if the relatively small potency of this venom on rabbit coagulation was species-specific and to determine if a component of the antivenom, RuCl<sub>3</sub>, would inhibit the fibrinogenolytic effects in a manner like that recently published with <italic toggle="yes">C. atrox</italic> venom [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>], including determining if <italic toggle="yes">C. m. molossus</italic> venom activity was Ca-independent. It should be noted that the materials, including plasma, used in those results [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>] were the same as in the present study. Preliminary experiments demonstrated that a <italic toggle="yes">C. m. molossus</italic> venom concentration of 24 &#x000b5;g/mL was required to diminish human plasmatic coagulation to the same extent as 3 &#x000b5;g/mL <italic toggle="yes">C. atrox</italic> venom [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>]. The results of these experiments are seen in <xref rid="toxins-17-00087-f006" ref-type="fig">Figure 6</xref>.</p><p>The venom of <italic toggle="yes">C. m. molossus</italic> degraded Na citrate anticoagulated human plasma prior to the addition of Ca to activate coagulation, demonstrating Ca-independent activity. The venom significantly increased TMRTG values (67%), decreased MRTG values (88%), and decreased TTG values (60%) compared to the control values. In sharp contrast, venom exposed to RuCl<sub>3</sub> generated thrombelastographic parameter values significantly different from the other two conditions, with greater TMRTG values (28%), smaller MRTG values (55%), and smaller TTG values (19%) compared to the control conditions. Thus, this venom was eight-fold less potent than <italic toggle="yes">C. atrox</italic> in human plasma in vitro [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>]. Lastly, RuCl<sub>3</sub> significantly inhibited the effects of <italic toggle="yes">C. m. molossus</italic> venom in vitro, verifying that the enzymes involved in the degradation of plasmatic function in rabbit plasma (<xref rid="toxins-17-00087-f005" ref-type="fig">Figure 5</xref>, <xref rid="toxins-17-00087-t001" ref-type="table">Table 1</xref>) were likely not inhibited in the one rabbit administered antivenom secondary to inadequate concentrations of ruthenium-based antivenom.</p></sec></sec><sec sec-type="discussion" id="sec7-toxins-17-00087"><title>7. Discussion</title><p>The de novo data derived from the characterization of <italic toggle="yes">C. m. molossus</italic> venom contribute to the impression that rattlesnake venom toxins are remarkably diverse, which, in turn, serves as a rationale for the use of POC thrombelastographic or other POC rapid hematological assessments to determine the degree of coagulation compromise of a snake bite victim. In the case of <italic toggle="yes">C. m. molossus</italic> venom, the thrombelastographic profile of loss of clot strength being primarily caused by decreased platelet-mediated clot strength and derangements in plasmatic coagulation kinetics without involving loss of plasma-mediated strength has been observed in rabbits administered intravenous <italic toggle="yes">C. atrox</italic> venom [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>]. The loss of platelet-mediated clot strength caused by <italic toggle="yes">C. atrox</italic> venom may be secondary to loss of responsivity secondary to a disintegrin [<xref rid="B22-toxins-17-00087" ref-type="bibr">22</xref>], aggregation by a c-type lectin [<xref rid="B25-toxins-17-00087" ref-type="bibr">25</xref>], and, likely, both. In contrast, platelet aggregation by <italic toggle="yes">C. m. molossus</italic> venom as originally reported argues strongly for a primarily c-type lectin-mediated effect in human platelets [<xref rid="B15-toxins-17-00087" ref-type="bibr">15</xref>] by this venom and in the inhibition of the rabbit whole-blood sample platelets of the present study. In contrast to the explainable effects of <italic toggle="yes">C. m. molossus</italic> and <italic toggle="yes">C. atrox</italic> venoms on platelets, the impact of the fibrinogen-modifying enzymes on the plasmatic coagulation of <italic toggle="yes">C. m. molossus</italic>, <italic toggle="yes">C. atrox</italic> [<xref rid="B32-toxins-17-00087" ref-type="bibr">32</xref>], and <italic toggle="yes">C. s. scutulatus</italic> [<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>] are qualitatively different. <italic toggle="yes">C. m. molossus</italic> and <italic toggle="yes">C. atrox</italic> [<xref rid="B32-toxins-17-00087" ref-type="bibr">32</xref>] prolong TMRTG values and MRTG values without affecting TTG, whereas <italic toggle="yes">C. s. scutulatus</italic> venom only significantly decreases MRTG and TTG values without changing TMRTG values [<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>]. Given that the progressive loss of fibrinogen from a plasma sample first decreases MRTG values and TTG values before TMRTG values increase in human plasma [<xref rid="B55-toxins-17-00087" ref-type="bibr">55</xref>], the modifications of fibrinogen by the metalloproteinases contained in <italic toggle="yes">C. m. molossus</italic> and <italic toggle="yes">C. atrox</italic> venoms change, but do not perhaps always eliminate, fibrinogen as a substrate for thrombin. Unlike the static system of in vitro exposure of plasma to venom, such as in this work (<xref rid="toxins-17-00087-f005" ref-type="fig">Figure 5</xref>), in the living circulation of a rabbit, these enzymes are only briefly exposed to some but not all fibrinogen prior to being redistributed. Thus, a mixture of normal fibrinogen, partially catalyzed fibrinogen, completely catalyzed fibrinogen, and various fibrinogen split products are present in vivo. In contrast to <italic toggle="yes">C. m. molossus</italic> and <italic toggle="yes">C. atrox</italic>, <italic toggle="yes">C. s. scutulatus</italic> venom diminishes MRTG and TTG values in plasma but does not affect whole-blood coagulation (with platelet activity) [<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>], which in part is likely secondary to a modification of fibrinogen that does not meaningfully affect fibrinogen&#x02013;platelet interactions. This concept of intact fibrinogen&#x02013;platelet interactions occurring despite partial catalysis of fibrinogen by <italic toggle="yes">C. s. scutulatus</italic> venom is strengthened by the observation that the fibrinogen eliminating, not modifying, serine protease of <italic toggle="yes">C. adamanteus</italic> venom, a thrombin-like enzyme, has been observed to not only decrease plasmatic coagulation kinetics but also diminish whole-blood coagulation kinetics without any platelet inhibiting compounds present [<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. When these data are considered, knowledge of the toxins of these diverse <italic toggle="yes">Crotalus</italic> venoms coupled with the coagulation kinetic profiles of the venom effects on POC thrombelastographic parameter values allows greater mechanistic insight into the effects of such venoms on critical fibrinogen modifications/elimination and fibrinogen&#x02013;platelet interactions.</p><p>There are limitations to the investigation of <italic toggle="yes">C. m. molossus</italic>, the most obvious being the inability to complete a full group of envenomed animals with antivenom treatment. Using all the venom in the acquired lot would have required obtaining far greater quantities of venom and performing at least twelve more experiments, which would have been a waste of animal life. Further, while there was not an apparent risk to the rabbits by the administration of such large quantities of venom, the administration of greater quantities of ruthenium-based antivenom would have required institutional approval and could have been potentially toxic, as recently reviewed in the earliest description of the model [<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>]. The paradigm to test envenomation and antivenom therapy was meant to simulate a bite on a rabbit-sized scale, but the bite was simulated with a 25 G needle, not large fangs, in a trauma-free manner. As recently reviewed [<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>], venoms can enter the central circulation a variety of ways, with lymphatic entry being predominant. However, if a venom proteome does not have the best combination of enzymes to gain lymphatic access, perhaps it is the intravenous absorption following the damage from a fang that facilitates systemic adsorption. The circumstances that the envenomed rabbits developed regional ecchymosis and required a tremendous amount of venom (40 mg/kg) to modestly affect coagulation may be evidence of the venom not being able to access the lymphatic system very well secondary to biochemical (lack of enzymes) or physical (venom trapped in the ecchymoses of tissues) impediments. The reality is that, if one was to treat an envenomation of an adult human being by this viper, the quantity of venom could never approach 40 mg/kg, and far more site-directed ruthenium antivenom could be safely administered to a human that may easily be 30&#x02013;50-fold larger than a 2&#x02013;3 kg rabbit. Another issue to consider is that not all venoms are meant to cause the death of their prey animals by severe, systemic coagulopathy. Instead, severe bleeding into the bite site and edema may cause shock and immobilization of prey. When considered as a whole, perhaps not all venoms are amenable to analysis with this rabbit model of minimal physical trespass, as it was designed to assess biochemical, not physical, contributions of envenomation to coagulopathy.</p><p>The goals of this review with inclusion of de novo data were to inform the readership about the malalignment of envenomed patient coagulation status with standard laboratory hemostasis tests and to use the example of rattlesnake envenomation of rabbits to illustrate the solution to this malalignment. In an environment containing vipers with diverse venom proteomes, there is uncertainty, especially regarding the Ca-dependence of key hemotoxins, and a reduction of &#x0201c;needle to activation time&#x0201d; is the most straightforward approach to eliminating this patient&#x02013;laboratory value malalignment. However, it is unreasonable to advocate that all emergency departments should invest in the POC thrombelastographic system featured in this article (<xref rid="toxins-17-00087-f002" ref-type="fig">Figure 2</xref>), especially given the frequency of envenomation at even the busiest hospital. Fortunately, there are several small, modular, desktop devices that can generate critical data derived from an envenomed patient that use either fresh blood samples or Na citrate anticoagulated blood (analyzed just a few minutes after collection), utilizing just a drop of blood, that are relatively inexpensive and require less frequent calibration or maintenance. A few such devices are displayed for the reader&#x02019;s convenience in <xref rid="toxins-17-00087-t002" ref-type="table">Table 2</xref>.</p><p>While this review has focused on Ca-independent protein-mediated degradation of coagulation involving rattlesnake venom, this potential problem for coagulation assessment involves many species of snake across the globe. The venom of vipers from the genera <italic toggle="yes">Agkistrodon</italic> [<xref rid="B56-toxins-17-00087" ref-type="bibr">56</xref>,<xref rid="B57-toxins-17-00087" ref-type="bibr">57</xref>,<xref rid="B58-toxins-17-00087" ref-type="bibr">58</xref>], <italic toggle="yes">Bothrops</italic> [<xref rid="B59-toxins-17-00087" ref-type="bibr">59</xref>,<xref rid="B60-toxins-17-00087" ref-type="bibr">60</xref>,<xref rid="B61-toxins-17-00087" ref-type="bibr">61</xref>,<xref rid="B62-toxins-17-00087" ref-type="bibr">62</xref>,<xref rid="B63-toxins-17-00087" ref-type="bibr">63</xref>,<xref rid="B64-toxins-17-00087" ref-type="bibr">64</xref>], <italic toggle="yes">Echis</italic> [<xref rid="B65-toxins-17-00087" ref-type="bibr">65</xref>,<xref rid="B66-toxins-17-00087" ref-type="bibr">66</xref>,<xref rid="B67-toxins-17-00087" ref-type="bibr">67</xref>,<xref rid="B68-toxins-17-00087" ref-type="bibr">68</xref>], <italic toggle="yes">Lachesis</italic> [<xref rid="B69-toxins-17-00087" ref-type="bibr">69</xref>,<xref rid="B70-toxins-17-00087" ref-type="bibr">70</xref>], <italic toggle="yes">Micropechis</italic> [<xref rid="B71-toxins-17-00087" ref-type="bibr">71</xref>], <italic toggle="yes">Naja</italic> [<xref rid="B72-toxins-17-00087" ref-type="bibr">72</xref>,<xref rid="B73-toxins-17-00087" ref-type="bibr">73</xref>,<xref rid="B74-toxins-17-00087" ref-type="bibr">74</xref>,<xref rid="B75-toxins-17-00087" ref-type="bibr">75</xref>,<xref rid="B76-toxins-17-00087" ref-type="bibr">76</xref>,<xref rid="B77-toxins-17-00087" ref-type="bibr">77</xref>,<xref rid="B78-toxins-17-00087" ref-type="bibr">78</xref>,<xref rid="B79-toxins-17-00087" ref-type="bibr">79</xref>,<xref rid="B80-toxins-17-00087" ref-type="bibr">80</xref>,<xref rid="B81-toxins-17-00087" ref-type="bibr">81</xref>], <italic toggle="yes">Oxyuranus</italic> [<xref rid="B82-toxins-17-00087" ref-type="bibr">82</xref>,<xref rid="B83-toxins-17-00087" ref-type="bibr">83</xref>], and <italic toggle="yes">Pseudonaja</italic> [<xref rid="B84-toxins-17-00087" ref-type="bibr">84</xref>,<xref rid="B85-toxins-17-00087" ref-type="bibr">85</xref>,<xref rid="B86-toxins-17-00087" ref-type="bibr">86</xref>] contains enzymatic and nonenzymatic proteins that can adversely affect plasmatic coagulation and platelet aggregation via Ca-independent mechanisms. There are many more examples, but the key issue is that assessment of coagulation with Na citrate or EDTA anticoagulated methods may have time-dependent degradation while awaiting assay worldwide.</p><p>In conclusion, it is anticipated that a reduction of &#x0201c;needle to activation time&#x0201d; with POC methodologies will provide new insights into the degree of damage done to envenomed patients&#x02019; coagulation. As can be observed with the POC thrombelastographic analyses of data derived from rabbits envenomed with four very different rattlesnake venom proteomes, insight into the nature of the toxin involved (e.g., platelet inactivation, fibrinogen-modifying) and the degree of coagulation compromise can be assessed without regard to the Ca-dependency of any specific toxin. Further, in addition to the findings of time-dependent, Ca-independent degradation of Na citrate anticoagulated human plasma sample coagulation by rattlesnake venom [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>], a similar loss of coagulation was observed in Na citrate anticoagulated plasma exposed to cobra venom [<xref rid="B81-toxins-17-00087" ref-type="bibr">81</xref>]. The thrombelastographic &#x0201c;finger print&#x0201d; of envenomation will depend on the effects of species-specific toxins, with different combinations of toxin potentially having the same &#x0201c;finger print.&#x0201d; Thus, as with all laboratory assessments, the clinical correlation with likely species responsible for envenomation must always be considered. The degree of inactivation of venom toxins by antivenoms, systemic (e.g., standard, antibody-based) or site-directed (e.g., ruthenium-based), may also be more accurately assessed, potentially obviating the need for the redosing of antivenom for concerns of coagulopathy. It is anticipated that future investigation and potential changes in clinical monitoring practices will improve the management of envenomed patients and assist in precision care.</p></sec><sec id="sec8-toxins-17-00087"><title>8. Materials and Methods</title><sec id="sec8dot1-toxins-17-00087"><title>8.1. Chemicals and Venoms</title><p>Lyophilized venom derived from an adult <italic toggle="yes">C. m. molossus</italic> was provided by the National Natural Toxins Research Center (NNTRC) located at Texas A&#x00026;M University-Kingsville, Kingsville, TX, USA. The author purchased twice as much venom as previously needed based on recent investigations with rattlesnake venoms [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. The National Institutes of Health fund the NNTRC out of the Office of Research Infrastructure Programs. Venom was dissolved into calcium-free phosphate buffered saline (PBS, Millipore Sigma, Saint Louis, MO, USA) to a final 60 mg/mL concentration, aliquoted, and maintained at &#x02212;80 &#x000b0;C. This made the venom twice as concentrated as in previous investigations [<xref rid="B35-toxins-17-00087" ref-type="bibr">35</xref>,<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>,<xref rid="B41-toxins-17-00087" ref-type="bibr">41</xref>] as a precaution to make sure that the volume of venom injections would not become problematic with the rabbit model utilized [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>] if the venom was markedly less potent than that of <italic toggle="yes">C. atrox</italic>. Pooled normal human plasma that was Na citrate anticoagulated and maintained at &#x02212;80 &#x000b0;C was obtained from George King Bio-Medical (Overland Park, KS, USA). Dimethyl sulfoxide (DMSO), tricarbonyldichlororuthenium (II) dimer (CORM-2), and RuCl<sub>3</sub> were obtained from Millipore Sigma (Saint Louis, MO, USA). Tissue factor for activating coagulation was obtained in the form of Pacific Hemostasis&#x02122; (Prothrombin Time Reagent, Thermo Fisher Scientific, Pittsburgh, PA, USA). CaCl<sub>2</sub> (200 mM) was obtained from Haemonetics Inc. (Braintree, MA, USA).</p></sec><sec id="sec8dot2-toxins-17-00087"><title>8.2. Rabbit Model</title><p>Male New Zealand White rabbits (2&#x02013;3 kg) were procured from Charles River Laboratories (San Diego, CA, USA) and housed within our animal facility and allowed food and water ad libitum for at least 1 week prior to experimentation. The reader is referred to the recent work for details concerning sedation, monitoring, envenomation, and antivenom administration [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>]. The initial dose of <italic toggle="yes">C. m. molossus</italic> venom was based on the value of <italic toggle="yes">C. atrox</italic> venom previously used successfully in this model to cause coagulopathy [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>], which was 4 mg/kg. The dose of venom was to be increased or decreased until a consistent pattern of coagulopathy was observed, which was then used for all subsequent experimentation. Blood samples were collected prior to venom injection and every hour for three hours in preliminary experiments, but this period was reduced to only one hour after venom injections after the dose for investigation was selected. If the animal was to be administered antivenom, then this occurred 5 min after injection of the venom, again administered through a 25G needle. After the last blood sample and vital sign assessments were obtained, the rabbits were euthanized with intravenous administration of 1 mL of pentobarbital/phenytoin (390/50 mg/mL) (Virbac, Westlake, TX, USA).</p></sec><sec id="sec8dot3-toxins-17-00087"><title>8.3. Coagulation Monitoring</title><sec id="sec8dot3dot1-toxins-17-00087"><title>8.3.1. Rabbit Blood Assessments</title><p>Thrombelastographic analyses were performed as recently described in [<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. Blood samples (1 mL) were collected and immediately placed into a thrombelastographic cup for analysis with a computer-controlled thrombelastograph<sup>&#x000ae;</sup> haemostasis system (Model 5000; Haemonetics Inc., Braintree, MA, USA) at 39 &#x000b0;C. The mixture used in the series of experiments was composed of 340 &#x000b5;L of whole blood, 10 &#x000b5;L of tissue factor (0.1% final concentration of Pacific Hemostasis&#x02122; Prothrombin Time Reagent, Thermo Fisher Scientific, Pittsburgh, PA, USA), and 10 &#x000b5;L of DMSO for samples without platelet inhibition or 10 &#x000b5;L of cytochalasin D (5 &#x000b5;M final concentration, dissolved in DMSO) in platelet-inhibited samples. After mixing the samples, the following parameters were determined: TMRTG (minutes), MRTG (dynes/cm<sup>2</sup>/second), and TTG (dynes/cm<sup>2</sup>). The %TTG<sub>Plasma</sub> was calculated by dividing the TTG value of a platelet-inhibited sample by the corresponding TTG value of the whole-blood sample without platelet inhibition as previously described [<xref rid="B38-toxins-17-00087" ref-type="bibr">38</xref>,<xref rid="B41-toxins-17-00087" ref-type="bibr">41</xref>]. The value of %TTG<sub>Platelet</sub> was calculated as 100% TTG<sub>Plasma</sub>. Data were collected for 30 min.</p></sec><sec id="sec8dot3dot2-toxins-17-00087"><title>8.3.2. Human Plasma Experiments</title><p>Plasma mixtures were placed in a disposable cup in a computer-controlled thrombelastograph<sup>&#x000ae;</sup> haemostasis system, as described previously, at 37 &#x000b0;C [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>]. The mixture used in the series of experiments was composed of 320 &#x000b5;L of plasma, 10 &#x000b5;L of tissue factor, 6.4 &#x000b5;L of PBS, 3.6 &#x000b5;L of venom solution, and, lastly, 20 &#x000b5;L of CaCl<sub>2</sub>. Plasma, tissue factor, and PBS were placed in the disposable cup, with venom solution added for 1 min prior to final addition of calcium chloride. Venom solutions were composed of 600&#x02013;2400 &#x000b5;g/mL venom in PBS that had no addition or had RuCl<sub>3</sub> placed as a 1% addition for a final concentration of 100 &#x000b5;M RuCl<sub>3</sub>. After the venom solutions were incubated at room temperature for 5 min, the aforementioned addition to the plasma mixture of the venom mixture was performed and the sample was mixed. Thus, the final concentration of venom in plasma was 6&#x02013;24 &#x000b5;g/mL, which was expected to cause fibrinogenolysis like that of <italic toggle="yes">C. atrox</italic> [<xref rid="B31-toxins-17-00087" ref-type="bibr">31</xref>]. After preliminary work, the three experimental conditions were a control condition, a venom condition, and a venom condition exposed to RuCl<sub>3</sub> condition. This brief exposure was designed to result in a reproducible compromise of coagulation that could be quickly assessed by the rapid onset of tissue factor-initiated clot formation. After CaCl<sub>2</sub> and final mixing of the samples, the previously described thrombelastographic parameters were determined. The data were collected for 15 min.</p></sec></sec><sec id="sec8dot4-toxins-17-00087"><title>8.4. Statistical Analyses</title><p>The data are presented as mean &#x000b1; SD. All experimental groups were represented by n = 6 different individuals, as this provides a statistical power &#x0003e; 0.8 with <italic toggle="yes">p</italic> &#x0003c; 0.05 using this methodology to assess differences in thrombelastographic parameters within and between groups [<xref rid="B33-toxins-17-00087" ref-type="bibr">33</xref>,<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>,<xref rid="B39-toxins-17-00087" ref-type="bibr">39</xref>]. The in vitro experiments had n = 4 per condition and had post hoc verification of a statistical power &#x0003e; 0.8 with <italic toggle="yes">p</italic> &#x0003c; 0.05. A commercially available statistical program was used for paired, two-tailed student&#x02019;s <italic toggle="yes">t</italic>-tests or one-way analyses of variance (ANOVA) as appropriate to the dataset, with ANOVA followed by Holm&#x02013;Sidak post hoc analyses (SigmaStat 3.1; Systat Software, Inc., San Jose, CA, USA). The graphics were generated with commercially available programs (Origen 2024, OrigenLab Corporation, Northampton, MA, USA, and CorelDRAW 2024, Alludo, Ottawa, ON, Canada). <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered significant.</p></sec></sec></body><back><ack><title>Acknowledgments</title><p>I acknowledge that the photographs of all the snakes presented in the figures were provided by the National Natural Toxins Research Center at Texas A&#x00026;M University-Kingsville, Kingsville, Texas, USA.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Institutional Review Board Statement</title><p>The Institutional Animal Care and Utilization Committee of the University of Arizona approved all procedures involving these rabbits (protocol #2022-0887, approved 8/9/2022). The protocol was conducted in accordance with all applicable federal and institutional policies, procedures, and regulations, including the PHS Policy on Humane Care and Use of Laboratory Animals, USDA regulations (9 CFR Parts 1, 2, 3), the Federal Animal Welfare Act (7 USC 2131 et. Seq.), the Guide for the Care and Use of Laboratory Animals, and all relevant institutional regulations and policies regarding animal care and use at the University of Arizona.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in this article. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The author is the inventor of the use of CORM-2 as a remedy for venom induced coagulopathy, with USPTO patents (#10,314,860 and #10,828,326) owned by the University of Arizona Board of Regents. Another patent involving the combination of RuCl3 with CORM-2 as a treatment for hemotoxic envenomation has been filed with the USPTO, also owned by the University of Arizona Board of Regents, with the author as inventor. The author is also the owner of a company, Trinity Antivenoms, LLC, that is inactive and that possesses no assets. These conflicts of interest are overseen by the University of Arizona&#x02019;s Office of Conflict of Interest, which has in place a plan for mitigation of conflicts that includes periodic reporting by the author and oversight by a colleague that is not involved with this project or any relevant patents to provide assurance of scientific integrity. Lastly, the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-toxins-17-00087"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phan</surname><given-names>P.</given-names></name>
<name><surname>Deshwal</surname><given-names>A.</given-names></name>
<name><surname>McMahon</surname><given-names>T.A.</given-names></name>
<name><surname>Slikas</surname><given-names>M.</given-names></name>
<name><surname>Andrews</surname><given-names>E.</given-names></name>
<name><surname>Becker</surname><given-names>B.</given-names></name>
<name><surname>Kumar</surname><given-names>T.K.S.</given-names></name>
</person-group><article-title>A Review of Rattlesnake Venoms</article-title><source>Toxins</source><year>2023</year><volume>16</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.3390/toxins16010002</pub-id><pub-id pub-id-type="pmid">38276526</pub-id>
</element-citation></ref><ref id="B2-toxins-17-00087"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willard</surname><given-names>N.K.</given-names></name>
<name><surname>Salazar</surname><given-names>E.</given-names></name>
<name><surname>Oyervides</surname><given-names>F.A.</given-names></name>
<name><surname>Wiebe</surname><given-names>C.S.</given-names></name>
<name><surname>Ocheltree</surname><given-names>J.S.</given-names></name>
<name><surname>Cortez</surname><given-names>M.</given-names></name>
<name><surname>Perez</surname><given-names>R.P.</given-names></name>
<name><surname>Markowitz</surname><given-names>H.</given-names></name>
<name><surname>Iliuk</surname><given-names>A.</given-names></name>
<name><surname>Sanchez</surname><given-names>E.E.</given-names></name>
<etal/>
</person-group><article-title>Proteomic Identification and Quantification of Snake Venom Biomarkers in Venom and Plasma Extracellular Vesicles</article-title><source>Toxins</source><year>2021</year><volume>13</volume><elocation-id>654</elocation-id><pub-id pub-id-type="doi">10.3390/toxins13090654</pub-id><pub-id pub-id-type="pmid">34564658</pub-id>
</element-citation></ref><ref id="B3-toxins-17-00087"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Queiroz</surname><given-names>M.R.</given-names></name>
<name><surname>de Sousa</surname><given-names>B.B.</given-names></name>
<name><surname>da Cunha Pereira</surname><given-names>D.F.</given-names></name>
<name><surname>Mamede</surname><given-names>C.C.N.</given-names></name>
<name><surname>Matias</surname><given-names>M.S.</given-names></name>
<name><surname>de Morais</surname><given-names>N.C.G.</given-names></name>
<name><surname>de Oliveira Costa</surname><given-names>J.</given-names></name>
<name><surname>de Oliveira</surname><given-names>F.</given-names></name>
</person-group><article-title>The role of platelets in hemostasis and the effects of snake venom toxins on platelet function</article-title><source>Toxicon</source><year>2017</year><volume>133</volume><fpage>33</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2017.04.013</pub-id><pub-id pub-id-type="pmid">28435120</pub-id>
</element-citation></ref><ref id="B4-toxins-17-00087"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Budzynski</surname><given-names>A.Z.</given-names></name>
<name><surname>Pandya</surname><given-names>B.V.</given-names></name>
<name><surname>Rubin</surname><given-names>R.N.</given-names></name>
<name><surname>Brizuela</surname><given-names>B.S.</given-names></name>
<name><surname>Soszka</surname><given-names>T.</given-names></name>
<name><surname>Stewart</surname><given-names>G.J.</given-names></name>
</person-group><article-title>Fibrinogenolytic afibrinogenemia after envenomation by western diamondback rattlesnake (<italic toggle="yes">Crotalus atrox</italic>)</article-title><source>Blood</source><year>1984</year><volume>63</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1182/blood.V63.1.1.1</pub-id><pub-id pub-id-type="pmid">6537796</pub-id>
</element-citation></ref><ref id="B5-toxins-17-00087"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyer</surname><given-names>L.V.</given-names></name>
<name><surname>Seifert</surname><given-names>S.A.</given-names></name>
<name><surname>Clark</surname><given-names>R.F.</given-names></name>
<name><surname>McNally</surname><given-names>J.T.</given-names></name>
<name><surname>Williams</surname><given-names>S.R.</given-names></name>
<name><surname>Nordt</surname><given-names>S.P.</given-names></name>
<name><surname>Walter</surname><given-names>F.G.</given-names></name>
<name><surname>Dart</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Recurrent and persistent coagulopathy following pit viper envenomation</article-title><source>Arch. Intern. Med.</source><year>1999</year><volume>159</volume><fpage>706</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1001/archinte.159.7.706</pub-id><pub-id pub-id-type="pmid">10218750</pub-id>
</element-citation></ref><ref id="B6-toxins-17-00087"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Odeleye</surname><given-names>A.A.</given-names></name>
<name><surname>Presley</surname><given-names>A.E.</given-names></name>
<name><surname>Passwater</surname><given-names>M.E.</given-names></name>
<name><surname>Mintz</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Report of two cases: Rattlesnake venom-induced thrombocytopenia</article-title><source>Ann. Clin. Lab. Sci.</source><year>2004</year><volume>34</volume><fpage>467</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">15648790</pub-id>
</element-citation></ref><ref id="B7-toxins-17-00087"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fazelat</surname><given-names>J.</given-names></name>
<name><surname>Teperman</surname><given-names>S.H.</given-names></name>
<name><surname>Touger</surname><given-names>M.</given-names></name>
</person-group><article-title>Recurrent hemorrhage after western diamondback rattlesnake envenomation treated with crotalidae polyvalent immune fab (ovine)</article-title><source>Clin. Toxicol.</source><year>2008</year><volume>46</volume><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1080/15563650701753849</pub-id><pub-id pub-id-type="pmid">18608290</pub-id>
</element-citation></ref><ref id="B8-toxins-17-00087"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glenn</surname><given-names>J.L.</given-names></name>
<name><surname>Straight</surname><given-names>R.</given-names></name>
</person-group><article-title>Mojave rattlesnake <italic toggle="yes">Crotalus scutulatus scutulatus</italic> venom: Variation in toxicity with geographical origin</article-title><source>Toxicon</source><year>1978</year><volume>16</volume><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/0041-0101(78)90065-X</pub-id><pub-id pub-id-type="pmid">622731</pub-id>
</element-citation></ref><ref id="B9-toxins-17-00087"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greene</surname><given-names>S.</given-names></name>
<name><surname>Gilbert</surname><given-names>M.</given-names></name>
<name><surname>Wolk</surname><given-names>B.</given-names></name>
<name><surname>Campleman</surname><given-names>S.</given-names></name>
<name><surname>Ruha</surname><given-names>A.M.</given-names></name>
<collab>ToxIC Snakebite Study Group</collab>
</person-group><article-title>Geographic variation in the clinical features of Mohave rattlesnake (<italic toggle="yes">Crotalus scutulatus</italic>) envenomations reported to the North American Snakebite Registry</article-title><source>Toxicon X</source><year>2023</year><volume>21</volume><fpage>100171</fpage><pub-id pub-id-type="doi">10.1016/j.toxcx.2023.100171</pub-id><pub-id pub-id-type="pmid">38047156</pub-id>
</element-citation></ref><ref id="B10-toxins-17-00087"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Massey</surname><given-names>D.J.</given-names></name>
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>S&#x000e1;nchez</surname><given-names>E.E.</given-names></name>
<name><surname>Sanz</surname><given-names>L.</given-names></name>
<name><surname>Richards</surname><given-names>K.</given-names></name>
<name><surname>Curtis</surname><given-names>R.</given-names></name>
<name><surname>Boesen</surname><given-names>K.</given-names></name>
</person-group><article-title>Venom variability and envenoming severity outcomes of the <italic toggle="yes">Crotalus scutulatus scutulatus</italic> (Mojave rattlesnake) from Southern Arizona</article-title><source>J. Proteom.</source><year>2012</year><volume>75</volume><fpage>2576</fpage><lpage>2587</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2012.02.035</pub-id><pub-id pub-id-type="pmid">22446891</pub-id>
</element-citation></ref><ref id="B11-toxins-17-00087"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hardy</surname><given-names>D.L.</given-names></name>
</person-group><article-title>Envenomation by the Mojave rattlesnake (<italic toggle="yes">Crotalus scutulatus scutulatus</italic>) in southern Arizona, U.S.A</article-title><source>Toxicon</source><year>1983</year><volume>21</volume><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/0041-0101(83)90054-5</pub-id><pub-id pub-id-type="pmid">6302953</pub-id>
</element-citation></ref><ref id="B12-toxins-17-00087"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weiss</surname><given-names>H.J.</given-names></name>
<name><surname>Allan</surname><given-names>S.</given-names></name>
<name><surname>Davidson</surname><given-names>E.</given-names></name>
<name><surname>Kochwa</surname><given-names>S.</given-names></name>
</person-group><article-title>Afibrinogenemia in man following the bite of a rattlesnake (<italic toggle="yes">Crotalus adamanteus</italic>)</article-title><source>Am. J. Med.</source><year>1969</year><volume>47</volume><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(69)90192-2</pub-id><pub-id pub-id-type="pmid">5822979</pub-id>
</element-citation></ref><ref id="B13-toxins-17-00087"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitchens</surname><given-names>C.S.</given-names></name>
<name><surname>Van Mierop</surname><given-names>L.H.</given-names></name>
</person-group><article-title>Mechanism of defibrination in humans after envenomation by the Eastern diamondback rattlesnake</article-title><source>Am. J. Hematol.</source><year>1983</year><volume>14</volume><fpage>345</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1002/ajh.2830140405</pub-id><pub-id pub-id-type="pmid">6859033</pub-id>
</element-citation></ref><ref id="B14-toxins-17-00087"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rushton</surname><given-names>W.F.</given-names></name>
<name><surname>Rivera</surname><given-names>J.V.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
<name><surname>Kurz</surname><given-names>M.C.</given-names></name>
<name><surname>Arnold</surname><given-names>J.</given-names></name>
</person-group><article-title>Utilization of thromboelastograms in management of <italic toggle="yes">Crotalus adamanteus</italic> envenomation</article-title><source>Clin. Toxicol.</source><year>2021</year><volume>59</volume><fpage>256</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1080/15563650.2020.1788053</pub-id></element-citation></ref><ref id="B15-toxins-17-00087"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hardy</surname><given-names>D.L.</given-names></name>
<name><surname>Jeter</surname><given-names>M.</given-names></name>
<name><surname>Corrigan</surname><given-names>J.J.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Envenomation by the northern blacktail rattlesnake (<italic toggle="yes">Crotalus molossus molossus</italic>): Report of two cases and the in vitro effects of the venom on fibrinolysis and platelet aggregation</article-title><source>Toxicon</source><year>1982</year><volume>20</volume><fpage>487</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1016/0041-0101(82)90012-5</pub-id><pub-id pub-id-type="pmid">7080054</pub-id>
</element-citation></ref><ref id="B16-toxins-17-00087"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yarema</surname><given-names>M.C.</given-names></name>
<name><surname>Curry</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Envenomation by the Northern Blacktail Rattlesnake (<italic toggle="yes">Crotalus molossus molossus</italic>): Case report</article-title><source>Pediatr. Emerg. Care</source><year>2005</year><volume>21</volume><fpage>40</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1097/01.pec.0000150989.03981.06</pub-id><pub-id pub-id-type="pmid">15643324</pub-id>
</element-citation></ref><ref id="B17-toxins-17-00087"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyer</surname><given-names>L.V.</given-names></name>
<name><surname>Chase</surname><given-names>P.B.</given-names></name>
<name><surname>Degan</surname><given-names>J.A.</given-names></name>
<name><surname>Figge</surname><given-names>G.</given-names></name>
<name><surname>Buelna-Romero</surname><given-names>A.</given-names></name>
<name><surname>Luchetti</surname><given-names>C.</given-names></name>
<name><surname>Alag&#x000f3;n</surname><given-names>A.</given-names></name>
</person-group><article-title>Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab&#x02019;)2 antivenoms</article-title><source>Toxicon</source><year>2013</year><volume>74</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2013.07.018</pub-id><pub-id pub-id-type="pmid">23948058</pub-id>
</element-citation></ref><ref id="B18-toxins-17-00087"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bush</surname><given-names>S.P.</given-names></name>
<name><surname>Ruha</surname><given-names>A.M.</given-names></name>
<name><surname>Seifert</surname><given-names>S.A.</given-names></name>
<name><surname>Morgan</surname><given-names>D.L.</given-names></name>
<name><surname>Lewis</surname><given-names>B.J.</given-names></name>
<name><surname>Arnold</surname><given-names>T.C.</given-names></name>
<name><surname>Clark</surname><given-names>R.F.</given-names></name>
<name><surname>Meggs</surname><given-names>W.J.</given-names></name>
<name><surname>Toschlog</surname><given-names>E.A.</given-names></name>
<name><surname>Borron</surname><given-names>S.W.</given-names></name>
<etal/>
</person-group><article-title>Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab&#x02019;)2 antivenoms</article-title><source>Clin. Toxicol.</source><year>2015</year><volume>53</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.3109/15563650.2014.974263</pub-id><pub-id pub-id-type="pmid">25361165</pub-id>
</element-citation></ref><ref id="B19-toxins-17-00087"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>C.W.</given-names></name>
<name><surname>Flach</surname><given-names>F.E.</given-names></name>
</person-group><article-title>Recurrent coagulopathy after rattlesnake bite requiring continuous intravenous dosing of antivenom</article-title><source>Case Rep. Emerg. Med.</source><year>2015</year><volume>2015</volume><fpage>719302</fpage><pub-id pub-id-type="doi">10.1155/2015/719302</pub-id><pub-id pub-id-type="pmid">25664187</pub-id>
</element-citation></ref><ref id="B20-toxins-17-00087"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pandya</surname><given-names>B.V.</given-names></name>
<name><surname>Rubin</surname><given-names>R.N.</given-names></name>
<name><surname>Olexa</surname><given-names>S.A.</given-names></name>
<name><surname>Budzynski</surname><given-names>A.Z.</given-names></name>
</person-group><article-title>Unique degradation of human fibrinogen by proteases from western diamondback rattlesnake (<italic toggle="yes">Crotalus atrox</italic>) venom</article-title><source>Toxicon</source><year>1983</year><volume>21</volume><fpage>515</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/0041-0101(83)90129-0</pub-id><pub-id pub-id-type="pmid">6353668</pub-id>
</element-citation></ref><ref id="B21-toxins-17-00087"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pandya</surname><given-names>B.V.</given-names></name>
<name><surname>Budzynski</surname><given-names>A.Z.</given-names></name>
</person-group><article-title>Anticoagulant proteases from western diamondback rattlesnake (<italic toggle="yes">Crotalus atrox</italic>) venom</article-title><source>Biochemistry</source><year>1984</year><volume>23</volume><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1021/bi00298a010</pub-id><pub-id pub-id-type="pmid">6367819</pub-id>
</element-citation></ref><ref id="B22-toxins-17-00087"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimokawa</surname><given-names>K.</given-names></name>
<name><surname>Jia</surname><given-names>L.G.</given-names></name>
<name><surname>Shannon</surname><given-names>J.D.</given-names></name>
<name><surname>Fox</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Isolation, sequence analysis, and biological activity of atrolysin E/D, the non-RGD disintegrin domain from <italic toggle="yes">Crotalus atrox</italic> venom</article-title><source>Arch. Biochem. Biophys.</source><year>1998</year><volume>354</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1006/abbi.1998.0698</pub-id><pub-id pub-id-type="pmid">9637732</pub-id>
</element-citation></ref><ref id="B23-toxins-17-00087"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szteiter</surname><given-names>S.S.</given-names></name>
<name><surname>Diego</surname><given-names>I.N.</given-names></name>
<name><surname>Ortegon</surname><given-names>J.</given-names></name>
<name><surname>Salinas</surname><given-names>E.M.</given-names></name>
<name><surname>Cirilo</surname><given-names>A.</given-names></name>
<name><surname>Reyes</surname><given-names>A.</given-names></name>
<name><surname>Sanchez</surname><given-names>O.</given-names></name>
<name><surname>Suntravat</surname><given-names>M.</given-names></name>
<name><surname>Salazar</surname><given-names>E.</given-names></name>
<name><surname>S&#x000e1;nchez</surname><given-names>E.E.</given-names></name>
<etal/>
</person-group><article-title>Examination of the Efficacy and Cross-Reactivity of a Novel Polyclonal Antibody Targeting the Disintegrin Domain in SVMPs to Neutralize Snake Venom</article-title><source>Toxins</source><year>2021</year><volume>13</volume><elocation-id>254</elocation-id><pub-id pub-id-type="doi">10.3390/toxins13040254</pub-id><pub-id pub-id-type="pmid">33807363</pub-id>
</element-citation></ref><ref id="B24-toxins-17-00087"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>M.C.</given-names></name>
<name><surname>Lin</surname><given-names>H.K.</given-names></name>
<name><surname>Peng</surname><given-names>H.C.</given-names></name>
<name><surname>Huang</surname><given-names>T.F.</given-names></name>
</person-group><article-title>Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of <italic toggle="yes">Crotalus atrox</italic></article-title><source>Blood</source><year>1998</year><volume>91</volume><fpage>1582</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1182/blood.V91.5.1582</pub-id><pub-id pub-id-type="pmid">9473223</pub-id>
</element-citation></ref><ref id="B25-toxins-17-00087"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ogilvie</surname><given-names>M.L.</given-names></name>
<name><surname>Byl</surname><given-names>J.W.</given-names></name>
<name><surname>Gartner</surname><given-names>T.K.</given-names></name>
</person-group><article-title>Platelet-aggregation is stimulated by lactose-inhibitable snake venom lectins</article-title><source>Thromb. Haemost.</source><year>1989</year><volume>62</volume><fpage>704</fpage><lpage>707</lpage><pub-id pub-id-type="pmid">2530646</pub-id>
</element-citation></ref><ref id="B26-toxins-17-00087"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Corrigan</surname><given-names>J.J.</given-names><suffix>Jr.</suffix></name>
<name><surname>Jeter</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Mojave rattlesnake (<italic toggle="yes">Crotalus scutulatus scutulatus</italic>) venom: In vitro effect on platelets, fibrinolysis, and fibrinogen clotting</article-title><source>Vet. Hum. Toxicol.</source><year>1990</year><volume>32</volume><fpage>439</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">2238441</pub-id>
</element-citation></ref><ref id="B27-toxins-17-00087"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e1;nchez</surname><given-names>E.E.</given-names></name>
<name><surname>Gal&#x000e1;n</surname><given-names>J.A.</given-names></name>
<name><surname>Russell</surname><given-names>W.K.</given-names></name>
<name><surname>Soto</surname><given-names>J.G.</given-names></name>
<name><surname>Russell</surname><given-names>D.H.</given-names></name>
<name><surname>P&#x000e9;rez</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Isolation and characterization of two disintegrins inhibiting ADP-induced human platelet aggregation from the venom of <italic toggle="yes">Crotalus scutulatus scutulatus</italic> (<italic toggle="yes">Mohave Rattlesnake</italic>)</article-title><source>Toxicol. Appl. Pharmacol.</source><year>2006</year><volume>212</volume><fpage>59</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2005.07.004</pub-id><pub-id pub-id-type="pmid">16084550</pub-id>
</element-citation></ref><ref id="B28-toxins-17-00087"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Damus</surname><given-names>P.S.</given-names></name>
<name><surname>Markland</surname><given-names>F.S.</given-names></name>
<name><surname>Davidson</surname><given-names>T.M.</given-names></name>
<name><surname>Shanley</surname><given-names>J.D.</given-names></name>
</person-group><article-title>A purified procoagulant enzyme from the venom of the eastern diamondback rattlesnake (<italic toggle="yes">Crotalus adamanteus</italic>): In vivo and in vitro studies</article-title><source>J. Lab. Clin. Med.</source><year>1972</year><volume>79</volume><fpage>906</fpage><lpage>923</lpage><pub-id pub-id-type="pmid">4623612</pub-id>
</element-citation></ref><ref id="B29-toxins-17-00087"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Margres</surname><given-names>M.J.</given-names></name>
<name><surname>McGivern</surname><given-names>J.J.</given-names></name>
<name><surname>Wray</surname><given-names>K.P.</given-names></name>
<name><surname>Seavy</surname><given-names>M.</given-names></name>
<name><surname>Calvin</surname><given-names>K.</given-names></name>
<name><surname>Rokyta</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Linking the transcriptome and proteome to characterize the venom of the eastern diamondback rattlesnake (<italic toggle="yes">Crotalus adamanteus</italic>)</article-title><source>J. Proteom.</source><year>2014</year><volume>96</volume><fpage>145</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.jprot.2013.11.001</pub-id></element-citation></ref><ref id="B30-toxins-17-00087"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suntravat</surname><given-names>M.</given-names></name>
<name><surname>Jia</surname><given-names>Y.</given-names></name>
<name><surname>Lucena</surname><given-names>S.E.</given-names></name>
<name><surname>S&#x000e1;nchez</surname><given-names>E.E.</given-names></name>
<name><surname>P&#x000e9;rez</surname><given-names>J.C.</given-names></name>
</person-group><article-title>cDNA cloning of a snake venom metalloproteinase from the eastern diamondback rattlesnake (<italic toggle="yes">Crotalus adamanteus</italic>), and the expression of its disintegrin domain with anti-platelet effects</article-title><source>Toxicon</source><year>2013</year><volume>64</volume><fpage>43</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2012.12.025</pub-id><pub-id pub-id-type="pmid">23313448</pub-id>
</element-citation></ref><ref id="B31-toxins-17-00087"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
<name><surname>Boyer</surname><given-names>L.V.</given-names></name>
</person-group><article-title>Iron and carbon monoxide attenuate degradation of plasmatic coagulation by <italic toggle="yes">Crotalus atrox</italic> venom</article-title><source>Blood Coagul. Fibrinolysis</source><year>2016</year><volume>27</volume><fpage>506</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1097/MBC.0000000000000440</pub-id><pub-id pub-id-type="pmid">26575491</pub-id>
</element-citation></ref><ref id="B32-toxins-17-00087"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
</person-group><article-title><italic toggle="yes">Crotalus atrox</italic> Venom Exposed to Carbon Monoxide Has Decreased Fibrinogenolytic Activity In Vivo in Rabbits</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2018</year><volume>122</volume><fpage>82</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1111/bcpt.12846</pub-id><pub-id pub-id-type="pmid">28691277</pub-id>
</element-citation></ref><ref id="B33-toxins-17-00087"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
</person-group><article-title>Ruthenium-based antivenom attenuates <italic toggle="yes">Crotalus atrox</italic> venom mediated coagulopathy in rabbits</article-title><source>Blood Coagul. Fibrinolysis</source><year>2024</year><volume>35</volume><fpage>167</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1097/MBC.0000000000001294</pub-id><pub-id pub-id-type="pmid">38477828</pub-id>
</element-citation></ref><ref id="B34-toxins-17-00087"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
</person-group><article-title>Carbon monoxide inhibits the anticoagulant activity of Mojave rattlesnake venoms type A and B</article-title><source>J. Thromb. Thrombolysis</source><year>2019</year><volume>48</volume><fpage>256</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/s11239-019-01887-w</pub-id><pub-id pub-id-type="pmid">31124031</pub-id>
</element-citation></ref><ref id="B35-toxins-17-00087"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
</person-group><article-title>Ruthenium chloride inhibits the anticoagulant activity of the phospholipase A<sub>2</sub>-dependent neurotoxin of Mojave rattlesnake Type A venom</article-title><source>J. Thromb. Thrombolysis</source><year>2021</year><volume>52</volume><fpage>1020</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1007/s11239-021-02479-3</pub-id><pub-id pub-id-type="pmid">33963978</pub-id>
</element-citation></ref><ref id="B36-toxins-17-00087"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
</person-group><article-title>Novel Toxicodynamic Model of Subcutaneous Envenomation to Characterize Snake Venom Coagulopathies and Assess the Efficacy of Site-Directed Inorganic Antivenoms</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>13939</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241813939</pub-id><pub-id pub-id-type="pmid">37762243</pub-id>
</element-citation></ref><ref id="B37-toxins-17-00087"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
<name><surname>Bazzell</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Carbon monoxide releasing molecule-2 inhibition of snake venom thrombin-like activity: Novel biochemical &#x0201c;brake&#x0201d;?</article-title><source>J. Thromb. Thrombolysis</source><year>2017</year><volume>43</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1007/s11239-016-1442-4</pub-id><pub-id pub-id-type="pmid">27787696</pub-id>
</element-citation></ref><ref id="B38-toxins-17-00087"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
</person-group><article-title>Carbon monoxide inhibits the anticoagulant activity of phospholipase A<sub>2</sub> purified from <italic toggle="yes">Crotalus adamanteus</italic> venom</article-title><source>J. Thromb. Thrombolysis</source><year>2019</year><volume>47</volume><fpage>73</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1007/s11239-018-1763-6</pub-id><pub-id pub-id-type="pmid">30374703</pub-id>
</element-citation></ref><ref id="B39-toxins-17-00087"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
</person-group><article-title>Ruthenium Antivenom Inhibits the Defibrinogenating Activity of <italic toggle="yes">Crotalus adamanteus</italic> Venom in Rabbits</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>6334</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25126334</pub-id><pub-id pub-id-type="pmid">38928044</pub-id>
</element-citation></ref><ref id="B40-toxins-17-00087"><label>40.</label><element-citation publication-type="webpage"><article-title>Animalia</article-title><comment>Available online: <ext-link xlink:href="https://animalia.bio/black-tailed-rattlesnake?property=176" ext-link-type="uri">https://animalia.bio/black-tailed-rattlesnake?property=176</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-14">(accessed on 14 December 2024)</date-in-citation></element-citation></ref><ref id="B41-toxins-17-00087"><label>41.</label><element-citation publication-type="webpage"><article-title>The Reptile Database</article-title><comment>Available online: <ext-link xlink:href="https://reptile-database.reptarium.cz/species?genus=Crotalus&#x00026;species=molossus" ext-link-type="uri">https://reptile-database.reptarium.cz/species?genus=Crotalus&#x00026;species=molossus</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-12-14">(accessed on 14 December 2024)</date-in-citation></element-citation></ref><ref id="B42-toxins-17-00087"><label>42.</label><element-citation publication-type="webpage"><article-title>Herpedia</article-title><comment>Available online: <ext-link xlink:href="https://www.herpedia.com/snakes/vipers/northern-black-tailed-rattlesnake.php" ext-link-type="uri">https://www.herpedia.com/snakes/vipers/northern-black-tailed-rattlesnake.php</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-14">(accessed on 14 May 2024)</date-in-citation></element-citation></ref><ref id="B43-toxins-17-00087"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rael</surname><given-names>E.D.</given-names></name>
<name><surname>Martinez</surname><given-names>M.</given-names></name>
<name><surname>Molina</surname><given-names>O.</given-names></name>
</person-group><article-title>Isolation of a fibrinolytic protease, M4, from venom of <italic toggle="yes">Crotalus molossus molossus</italic> (northern blacktail rattlesnake)</article-title><source>Haemostasis</source><year>1992</year><volume>22</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1159/000216290</pub-id><pub-id pub-id-type="pmid">1521826</pub-id>
</element-citation></ref><ref id="B44-toxins-17-00087"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Rael</surname><given-names>E.D.</given-names></name>
</person-group><article-title>Purification of M5, a fibrinolytic proteinase from <italic toggle="yes">Crotalus molossus molossus</italic> venom that attacks complement</article-title><source>Int. J. Biochem. Cell Biol.</source><year>1997</year><volume>29</volume><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(96)00139-2</pub-id><pub-id pub-id-type="pmid">9251246</pub-id>
</element-citation></ref><ref id="B45-toxins-17-00087"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e1;nchez</surname><given-names>E.E.</given-names></name>
<name><surname>Soliz</surname><given-names>L.A.</given-names></name>
<name><surname>Ram&#x000ed;rez</surname><given-names>M.S.</given-names></name>
<name><surname>P&#x000e9;rez</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Partial characterization of a basic protein from <italic toggle="yes">Crotalus molossus molossus</italic> (northern blacktail rattlesnake) venom and production of a monoclonal antibody</article-title><source>Toxicon</source><year>2001</year><volume>39</volume><fpage>523</fpage><lpage>537</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(00)00165-3</pub-id><pub-id pub-id-type="pmid">11024493</pub-id>
</element-citation></ref><ref id="B46-toxins-17-00087"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rael</surname><given-names>E.D.</given-names></name>
<name><surname>Rivas</surname><given-names>J.Z.</given-names></name>
<name><surname>Chen</surname><given-names>T.</given-names></name>
<name><surname>Maddux</surname><given-names>N.</given-names></name>
<name><surname>Huizar</surname><given-names>E.</given-names></name>
<name><surname>Lieb</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Differences in fibrinolysis and complement inactivation by venom from different northern blacktailed rattlesnakes (<italic toggle="yes">Crotalus molossus molossus</italic>)</article-title><source>Toxicon</source><year>1997</year><volume>35</volume><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(96)00139-0</pub-id><pub-id pub-id-type="pmid">9133705</pub-id>
</element-citation></ref><ref id="B47-toxins-17-00087"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
<name><surname>Stratton</surname><given-names>D.L.</given-names></name>
<name><surname>Hoelscher</surname><given-names>T.M.</given-names></name>
<name><surname>Nakamura</surname><given-names>H.L.</given-names></name>
<name><surname>Cornelison</surname><given-names>M.M.</given-names></name>
<name><surname>Rushton</surname><given-names>W.F.</given-names></name>
<name><surname>Smelski</surname><given-names>G.T.</given-names></name>
</person-group><article-title>Antivenom Administration After Rattlesnake Envenoming in Arizona Does Not Directly Diminish Pain</article-title><source>Toxins</source><year>2024</year><volume>16</volume><elocation-id>521</elocation-id><pub-id pub-id-type="doi">10.3390/toxins16120521</pub-id><pub-id pub-id-type="pmid">39728779</pub-id>
</element-citation></ref><ref id="B48-toxins-17-00087"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aitchison</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Boomslang bite--diagnosis and management. A report of 2 cases</article-title><source>S. Afr. Med. J.</source><year>1990</year><volume>78</volume><fpage>39</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">2363083</pub-id>
</element-citation></ref><ref id="B49-toxins-17-00087"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Walker</surname><given-names>N.P.</given-names></name>
<name><surname>Bradlow</surname><given-names>B.A.</given-names></name>
<name><surname>Atkinson</surname><given-names>P.M.</given-names></name>
</person-group><article-title>A rapid chromogenic method for the determination of prothrombin precursor in plasma</article-title><source>Am. J. Clin. Pathol.</source><year>1982</year><volume>78</volume><fpage>777</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1093/ajcp/78.5.777</pub-id><pub-id pub-id-type="pmid">7137122</pub-id>
</element-citation></ref><ref id="B50-toxins-17-00087"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
<name><surname>Frank</surname><given-names>N.</given-names></name>
</person-group><article-title>Differential heme-mediated modulation of <italic toggle="yes">Deinagkistrodon</italic>, <italic toggle="yes">Dispholidus</italic>, <italic toggle="yes">Protobothrops</italic> and <italic toggle="yes">Pseudonaja</italic> hemotoxic venom activity in human plasma</article-title><source>Biometals</source><year>2018</year><volume>31</volume><fpage>951</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1007/s10534-018-0137-z</pub-id><pub-id pub-id-type="pmid">30132273</pub-id>
</element-citation></ref><ref id="B51-toxins-17-00087"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Talalak</surname><given-names>P.</given-names></name>
</person-group><article-title>Action of <italic toggle="yes">Trimeresurus erythrusus</italic> and <italic toggle="yes">Trimeresurus popeorum</italic> venom on blood coagulation</article-title><source>J. Med. Assoc. Thail.</source><year>1977</year><volume>60</volume><fpage>9</fpage><lpage>18</lpage></element-citation></ref><ref id="B52-toxins-17-00087"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ouyang</surname><given-names>C.</given-names></name>
<name><surname>Teng</surname><given-names>C.M.</given-names></name>
<name><surname>Chen</surname><given-names>Y.C.</given-names></name>
<name><surname>Lin</surname><given-names>S.C.</given-names></name>
</person-group><article-title>Purification and characterization of the anticoagulant principle of <italic toggle="yes">Trimeresurus mucrosquamatus</italic> venom</article-title><source>Biochim. Biophys. Acta</source><year>1978</year><volume>541</volume><fpage>394</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(78)90198-8</pub-id><pub-id pub-id-type="pmid">667129</pub-id>
</element-citation></ref><ref id="B53-toxins-17-00087"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
<name><surname>Frank</surname><given-names>N.</given-names></name>
<name><surname>Matika</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Effects of Heme Modulation on <italic toggle="yes">Ovophis</italic> and <italic toggle="yes">Trimeresurus</italic> Venom Activity in Human Plasma</article-title><source>Toxins</source><year>2018</year><volume>10</volume><elocation-id>322</elocation-id><pub-id pub-id-type="doi">10.3390/toxins10080322</pub-id><pub-id pub-id-type="pmid">30096756</pub-id>
</element-citation></ref><ref id="B54-toxins-17-00087"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Consroe</surname><given-names>P.</given-names></name>
<name><surname>Gerrish</surname><given-names>K.</given-names></name>
<name><surname>Egem</surname><given-names>M.</given-names></name>
<name><surname>Russell</surname><given-names>F.E.</given-names></name>
</person-group><article-title>Intravenous dose-lethality study of American pit viper venoms in mice using standardized methods</article-title><source>J. Wilderness Med.</source><year>1992</year><volume>3</volume><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1580/0953-9859-3.2.162</pub-id></element-citation></ref><ref id="B55-toxins-17-00087"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>V.G.</given-names></name>
<name><surname>Cohen</surname><given-names>B.M.</given-names></name>
<name><surname>Cohen</surname><given-names>E.</given-names></name>
</person-group><article-title>Effects of coagulation factor deficiency on plasma coagulation kinetics determined via Thrombelastography<sup>&#x000ae;</sup>: Critical roles of fibrinogen and Factors II, VII, X and XII</article-title><source>Acta Anaesthesiol. Scand.</source><year>2005</year><volume>49</volume><fpage>222</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1111/j.1399-6576.2005.00602.x</pub-id><pub-id pub-id-type="pmid">15715625</pub-id>
</element-citation></ref><ref id="B56-toxins-17-00087"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>F.</given-names></name>
<name><surname>Shen</surname><given-names>B.</given-names></name>
<name><surname>Zhu</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Ji</surname><given-names>Y.</given-names></name>
<name><surname>Niu</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Teng</surname><given-names>M.</given-names></name>
</person-group><article-title>Crystal structure and activating effect on RyRs of AhV_TL-I, a glycosylated thrombin-like enzyme from <italic toggle="yes">Agkistrodon halys</italic> snake venom</article-title><source>Arch. Toxicol.</source><year>2013</year><volume>87</volume><fpage>535</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1007/s00204-012-0957-5</pub-id><pub-id pub-id-type="pmid">23052203</pub-id>
</element-citation></ref><ref id="B57-toxins-17-00087"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W.J.</given-names></name>
<name><surname>Huang</surname><given-names>T.F.</given-names></name>
</person-group><article-title>A novel tetrameric venom protein, agglucetin from <italic toggle="yes">Agkistrodon acutus</italic>, acts as a glycoprotein Ib agonist</article-title><source>Thromb. Haemost.</source><year>2001</year><volume>86</volume><fpage>1077</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1055/s-0037-1616536</pub-id><pub-id pub-id-type="pmid">11686327</pub-id>
</element-citation></ref><ref id="B58-toxins-17-00087"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>T.F.</given-names></name>
<name><surname>Yeh</surname><given-names>H.I.</given-names></name>
<name><surname>Ouyang</surname><given-names>C.</given-names></name>
</person-group><article-title>Mechanism of action of the platelet aggregation inhibitor purified from <italic toggle="yes">Agkistrodon halys</italic> (mamushi) snake venom</article-title><source>Toxicon</source><year>1984</year><volume>22</volume><fpage>243</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/0041-0101(84)90025-4</pub-id><pub-id pub-id-type="pmid">6427979</pub-id>
</element-citation></ref><ref id="B59-toxins-17-00087"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borges</surname><given-names>R.J.</given-names></name>
<name><surname>Salvador</surname><given-names>G.H.M.</given-names></name>
<name><surname>Campanelli</surname><given-names>H.B.</given-names></name>
<name><surname>Pimenta</surname><given-names>D.C.</given-names></name>
<name><surname>de Oliveira Neto</surname><given-names>M.</given-names></name>
<name><surname>Us&#x000f3;n</surname><given-names>I.</given-names></name>
<name><surname>Fontes</surname><given-names>M.R.M.</given-names></name>
</person-group><article-title>BthTX-II from <italic toggle="yes">Bothrops jararacussu</italic> venom has variants with different oligomeric assemblies: An example of snake venom phospholipases A<sub>2</sub> versatility</article-title><source>Int. J. Biol. Macromol.</source><year>2021</year><volume>191</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.09.083</pub-id><pub-id pub-id-type="pmid">34547312</pub-id>
</element-citation></ref><ref id="B60-toxins-17-00087"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira</surname><given-names>T.L.</given-names></name>
<name><surname>Ruller</surname><given-names>R.</given-names></name>
<name><surname>Chioato</surname><given-names>L.</given-names></name>
<name><surname>Ward</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Insights on calcium-independent phospholipid membrane damage by Lys49-PLA<sub>2</sub> using tryptophan scanning mutagenesis of bothropstoxin-I from <italic toggle="yes">Bothrops jararacussu</italic></article-title><source>Biochimie</source><year>2008</year><volume>90</volume><fpage>1397</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2007.10.012</pub-id><pub-id pub-id-type="pmid">18036350</pub-id>
</element-citation></ref><ref id="B61-toxins-17-00087"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Pestina</surname><given-names>T.I.</given-names></name>
<name><surname>Berndt</surname><given-names>M.C.</given-names></name>
<name><surname>Steward</surname><given-names>S.A.</given-names></name>
<name><surname>Jackson</surname><given-names>C.W.</given-names></name>
<name><surname>Gartner</surname><given-names>T.K.</given-names></name>
</person-group><article-title>The roles of ADP and TXA in botrocetin/VWF-induced aggregation of washed platelets</article-title><source>J. Thromb. Haemost.</source><year>2004</year><volume>2</volume><fpage>2213</fpage><lpage>2222</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.01023.x</pub-id><pub-id pub-id-type="pmid">15613029</pub-id>
</element-citation></ref><ref id="B62-toxins-17-00087"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monteiro</surname><given-names>R.Q.</given-names></name>
<name><surname>Bock</surname><given-names>P.E.</given-names></name>
<name><surname>Bianconi</surname><given-names>M.L.</given-names></name>
<name><surname>Zingali</surname><given-names>R.B.</given-names></name>
</person-group><article-title>Characterization of bothrojaracin interaction with human prothrombin</article-title><source>Protein Sci.</source><year>2001</year><volume>10</volume><fpage>1897</fpage><lpage>1904</lpage><pub-id pub-id-type="doi">10.1110/ps.09001</pub-id><pub-id pub-id-type="pmid">11514680</pub-id>
</element-citation></ref><ref id="B63-toxins-17-00087"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arocas</surname><given-names>V.</given-names></name>
<name><surname>Zingali</surname><given-names>R.B.</given-names></name>
<name><surname>Guillin</surname><given-names>M.C.</given-names></name>
<name><surname>Bon</surname><given-names>C.</given-names></name>
<name><surname>Jandrot-Perrus</surname><given-names>M.</given-names></name>
</person-group><article-title>Bothrojaracin: A potent two-site-directed thrombin inhibitor</article-title><source>Biochemistry</source><year>1996</year><volume>35</volume><fpage>9083</fpage><lpage>9089</lpage><pub-id pub-id-type="doi">10.1021/bi960043l</pub-id><pub-id pub-id-type="pmid">8703912</pub-id>
</element-citation></ref><ref id="B64-toxins-17-00087"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Azevedo</surname><given-names>W.F.</given-names><suffix>Jr.</suffix></name>
<name><surname>Ward</surname><given-names>R.J.</given-names></name>
<name><surname>Canduri</surname><given-names>F.</given-names></name>
<name><surname>Soares</surname><given-names>A.</given-names></name>
<name><surname>Giglio</surname><given-names>J.R.</given-names></name>
<name><surname>Arni</surname><given-names>R.K.</given-names></name>
</person-group><article-title>Crystal structure of piratoxin-I: A calcium-independent, myotoxic phospholipase A<sub>2</sub>-homologue from <italic toggle="yes">Bothrops pirajai</italic> venom</article-title><source>Toxicon</source><year>1998</year><volume>36</volume><fpage>1395</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(98)00017-8</pub-id><pub-id pub-id-type="pmid">9723838</pub-id>
</element-citation></ref><ref id="B65-toxins-17-00087"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makhoul</surname><given-names>S.</given-names></name>
<name><surname>Trabold</surname><given-names>K.</given-names></name>
<name><surname>Gambaryan</surname><given-names>S.</given-names></name>
<name><surname>Tenzer</surname><given-names>S.</given-names></name>
<name><surname>Pillitteri</surname><given-names>D.</given-names></name>
<name><surname>Walter</surname><given-names>U.</given-names></name>
<name><surname>Jurk</surname><given-names>K.</given-names></name>
</person-group><article-title>cAMP- and cGMP-elevating agents inhibit GPIb&#x003b1;-mediated aggregation but not GPIb&#x003b1;-stimulated Syk activation in human platelets</article-title><source>Cell Commun. Signal.</source><year>2019</year><volume>17</volume><fpage>122</fpage><pub-id pub-id-type="doi">10.1186/s12964-019-0428-1</pub-id><pub-id pub-id-type="pmid">31519182</pub-id>
</element-citation></ref><ref id="B66-toxins-17-00087"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Atoda</surname><given-names>H.</given-names></name>
<name><surname>Kaneko</surname><given-names>H.</given-names></name>
<name><surname>Mizuno</surname><given-names>H.</given-names></name>
<name><surname>Morita</surname><given-names>T.</given-names></name>
</person-group><article-title>Calcium-binding analysis and molecular modeling reveal <italic toggle="yes">echis</italic> coagulation factor IX/factor X-binding protein has the Ca-binding properties and Ca ion-independent folding of other C-type lectin-like proteins</article-title><source>FEBS Lett.</source><year>2002</year><volume>531</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(02)03507-X</pub-id><pub-id pub-id-type="pmid">12417317</pub-id>
</element-citation></ref><ref id="B67-toxins-17-00087"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>D.</given-names></name>
<name><surname>Sekiya</surname><given-names>F.</given-names></name>
<name><surname>Morita</surname><given-names>T.</given-names></name>
</person-group><article-title>Prothrombin and factor X activator activities in the venoms of Viperidae snakes</article-title><source>Toxicon</source><year>1997</year><volume>35</volume><fpage>1581</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(97)00043-3</pub-id><pub-id pub-id-type="pmid">9428105</pub-id>
</element-citation></ref><ref id="B68-toxins-17-00087"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirchhof</surname><given-names>B.</given-names></name>
<name><surname>Schmale</surname><given-names>S.</given-names></name>
<name><surname>van de Loo</surname><given-names>J.</given-names></name>
</person-group><article-title>Determination of prothrombin by a micro-coagulation method</article-title><source>Haemostasis</source><year>1983</year><volume>13</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000214697</pub-id><pub-id pub-id-type="pmid">6840624</pub-id>
</element-citation></ref><ref id="B69-toxins-17-00087"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magalhaes</surname><given-names>A.</given-names></name>
<name><surname>Ferreira</surname><given-names>R.N.</given-names></name>
<name><surname>Richardson</surname><given-names>M.</given-names></name>
<name><surname>Gontijo</surname><given-names>S.</given-names></name>
<name><surname>Yarleque</surname><given-names>A.</given-names></name>
<name><surname>Magalhaes</surname><given-names>H.P.</given-names></name>
<name><surname>Bloch</surname><given-names>C.</given-names></name>
<name><surname>Sanchez</surname><given-names>E.F.</given-names></name>
</person-group><article-title>Coagulant thrombin-like enzymes from the venoms of Brazilian and Peruvian bushmaster (<italic toggle="yes">Lachesis muta muta</italic>) snakes</article-title><source>Comp. Biochem. Physiol. B Biochem. Mol. Biol.</source><year>2003</year><volume>136</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/S1096-4959(03)00202-1</pub-id><pub-id pub-id-type="pmid">14529751</pub-id>
</element-citation></ref><ref id="B70-toxins-17-00087"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Magalh&#x000e3;es</surname><given-names>A.</given-names></name>
<name><surname>Monteiro</surname><given-names>M.R.</given-names></name>
<name><surname>Magalh&#x000e3;es</surname><given-names>H.P.</given-names></name>
<name><surname>Mares-Guia</surname><given-names>M.</given-names></name>
<name><surname>Rogana</surname><given-names>E.</given-names></name>
</person-group><article-title>Thrombin-like enzyme from <italic toggle="yes">Lachesis muta muta</italic> venom: Isolation and topographical analysis of its active site structure by means of the binding of amidines and guanidines as competitive inhibitors</article-title><source>Toxicon</source><year>1997</year><volume>35</volume><fpage>1549</fpage><lpage>1559</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(97)00003-2</pub-id><pub-id pub-id-type="pmid">9428102</pub-id>
</element-citation></ref><ref id="B71-toxins-17-00087"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>R.</given-names></name>
<name><surname>Manjunatha</surname><given-names>K.R.</given-names></name>
<name><surname>Gopalakrishnakone</surname><given-names>P.</given-names></name>
</person-group><article-title>A novel prothrombin activator from the venom of <italic toggle="yes">Micropechis ikaheka</italic>: Isolation and characterization</article-title><source>Arch. Biochem. Biophys.</source><year>2002</year><volume>408</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S0003-9861(02)00447-2</pub-id><pub-id pub-id-type="pmid">12485606</pub-id>
</element-citation></ref><ref id="B72-toxins-17-00087"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>M.S.</given-names></name>
<name><surname>Girish</surname><given-names>K.S.</given-names></name>
<name><surname>Vishwanath</surname><given-names>B.S.</given-names></name>
<name><surname>Kemparaju</surname><given-names>K.</given-names></name>
</person-group><article-title>The metalloprotease, NN-PF3 from <italic toggle="yes">Naja naja</italic> venom inhibits platelet aggregation primarily by affecting &#x003b1;2&#x003b2;1 integrin</article-title><source>Ann. Hematol.</source><year>2011</year><volume>90</volume><fpage>569</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1007/s00277-010-1103-1</pub-id><pub-id pub-id-type="pmid">20957364</pub-id>
</element-citation></ref><ref id="B73-toxins-17-00087"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jagadeesha</surname><given-names>D.K.</given-names></name>
<name><surname>Shashidhara murthy</surname><given-names>R.</given-names></name>
<name><surname>Girish</surname><given-names>K.S.</given-names></name>
<name><surname>Kemparaju</surname><given-names>K.</given-names></name>
</person-group><article-title>A non-toxic anticoagulant metalloprotease: Purification and characterization from Indian cobra (<italic toggle="yes">Naja naja naja</italic>) venom</article-title><source>Toxicon</source><year>2002</year><volume>40</volume><fpage>667</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1016/S0041-0101(01)00216-1</pub-id><pub-id pub-id-type="pmid">12175602</pub-id>
</element-citation></ref><ref id="B74-toxins-17-00087"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Evans</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Purification and properties of a fibrinogenase from the venom of <italic toggle="yes">Naja nigricollis</italic></article-title><source>Biochim. Biophys. Acta</source><year>1984</year><volume>802</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(84)90032-1</pub-id><pub-id pub-id-type="pmid">6435687</pub-id>
</element-citation></ref><ref id="B75-toxins-17-00087"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teng</surname><given-names>C.M.</given-names></name>
<name><surname>Jy</surname><given-names>W.</given-names></name>
<name><surname>Ouyang</surname><given-names>C.</given-names></name>
</person-group><article-title>Cardiotoxin from <italic toggle="yes">Naja naja atra</italic> snake venom: A potentiator of platelet aggregation</article-title><source>Toxicon</source><year>1984</year><volume>22</volume><fpage>463</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/0041-0101(84)90090-4</pub-id><pub-id pub-id-type="pmid">6474495</pub-id>
</element-citation></ref><ref id="B76-toxins-17-00087"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>X.J.</given-names></name>
<name><surname>Wang</surname><given-names>C.E.</given-names></name>
<name><surname>Li</surname><given-names>Y.N.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.Y.</given-names></name>
<name><surname>Sun</surname><given-names>Q.Y.</given-names></name>
</person-group><article-title>Atrase A, a P-III class metalloproteinase purified from cobra venom, exhibits potent anticoagulant activity by inhibiting coagulation pathway and activating the fibrinolytic system</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e30969</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e30969</pub-id><pub-id pub-id-type="pmid">38813202</pub-id>
</element-citation></ref><ref id="B77-toxins-17-00087"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kazandjian</surname><given-names>T.D.</given-names></name>
<name><surname>Arrahman</surname><given-names>A.</given-names></name>
<name><surname>Still</surname><given-names>K.B.M.</given-names></name>
<name><surname>Somsen</surname><given-names>G.W.</given-names></name>
<name><surname>Vonk</surname><given-names>F.J.</given-names></name>
<name><surname>Casewell</surname><given-names>N.R.</given-names></name>
<name><surname>Wilkinson</surname><given-names>M.C.</given-names></name>
<name><surname>Kool</surname><given-names>J.</given-names></name>
</person-group><article-title>Anticoagulant Activity of <italic toggle="yes">Naja nigricollis</italic> Venom Is Mediated by Phospholipase A<sub>2</sub> Toxins and Inhibited by Varespladib</article-title><source>Toxins</source><year>2021</year><volume>13</volume><elocation-id>302</elocation-id><pub-id pub-id-type="doi">10.3390/toxins13050302</pub-id><pub-id pub-id-type="pmid">33922825</pub-id>
</element-citation></ref><ref id="B78-toxins-17-00087"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>Q.Y.</given-names></name>
<name><surname>Wang</surname><given-names>C.E.</given-names></name>
<name><surname>Li</surname><given-names>Y.N.</given-names></name>
<name><surname>Bao</surname><given-names>J.</given-names></name>
</person-group><article-title>Inhibition of platelet aggregation and blood coagulation by a P-III class metalloproteinase purified from <italic toggle="yes">Naja atra</italic> venom</article-title><source>Toxicon</source><year>2020</year><volume>187</volume><fpage>223</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2020.09.009</pub-id><pub-id pub-id-type="pmid">32971099</pub-id>
</element-citation></ref><ref id="B79-toxins-17-00087"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chanda</surname><given-names>C.</given-names></name>
<name><surname>Sarkar</surname><given-names>A.</given-names></name>
<name><surname>Chakrabarty</surname><given-names>D.</given-names></name>
</person-group><article-title>Thrombolytic protein from cobra venom with anti-adhesive properties</article-title><source>Arch. Biochem. Biophys.</source><year>2016</year><volume>590</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2015.11.006</pub-id><pub-id pub-id-type="pmid">26558696</pub-id>
</element-citation></ref><ref id="B80-toxins-17-00087"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dutta</surname><given-names>S.</given-names></name>
<name><surname>Gogoi</surname><given-names>D.</given-names></name>
<name><surname>Mukherjee</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Anticoagulant mechanism and platelet deaggregation property of a non-cytotoxic, acidic phospholipase A<sub>2</sub> purified from Indian cobra (<italic toggle="yes">Naja naja</italic>) venom: Inhibition of anticoagulant activity by low molecular weight heparin</article-title><source>Biochimie</source><year>2015</year><volume>110</volume><fpage>93</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2014.12.020</pub-id><pub-id pub-id-type="pmid">25576831</pub-id>
</element-citation></ref><ref id="B81-toxins-17-00087"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asad</surname><given-names>M.H.</given-names></name>
<name><surname>Razi</surname><given-names>M.T.</given-names></name>
<name><surname>Khan</surname><given-names>T.</given-names></name>
<name><surname>Najam-Us-saqib</surname><given-names>Q.</given-names></name>
<name><surname>Murtaza</surname><given-names>G.</given-names></name>
<name><surname>Hussain</surname><given-names>M.S.</given-names></name>
<name><surname>Hussain</surname><given-names>M.S.</given-names></name>
<name><surname>Karim</surname><given-names>S.</given-names></name>
<name><surname>Hussain</surname><given-names>I.</given-names></name>
</person-group><article-title>Coagulopathies in <italic toggle="yes">Naja naja karachiensis</italic> (black Pakistan cobra) bites and its effect on coagulation tests upon storage of platelet-poor plasma</article-title><source>Acta Pol. Pharm.</source><year>2012</year><volume>69</volume><fpage>1031</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">23285662</pub-id>
</element-citation></ref><ref id="B82-toxins-17-00087"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chester</surname><given-names>A.</given-names></name>
<name><surname>Crawford</surname><given-names>G.P.</given-names></name>
</person-group><article-title>In vitro coagulant properties of venoms from Australian snakes</article-title><source>Toxicon</source><year>1982</year><volume>20</volume><fpage>501</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/0041-0101(82)90014-9</pub-id><pub-id pub-id-type="pmid">7080056</pub-id>
</element-citation></ref><ref id="B83-toxins-17-00087"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zdenek</surname><given-names>C.N.</given-names></name>
<name><surname>den Brouw</surname><given-names>B.O.</given-names></name>
<name><surname>Dashevsky</surname><given-names>D.</given-names></name>
<name><surname>Gloria</surname><given-names>A.</given-names></name>
<name><surname>Youngman</surname><given-names>N.J.</given-names></name>
<name><surname>Watson</surname><given-names>E.</given-names></name>
<name><surname>Green</surname><given-names>P.</given-names></name>
<name><surname>Hay</surname><given-names>C.</given-names></name>
<name><surname>Dunstan</surname><given-names>N.</given-names></name>
<name><surname>Allen</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Clinical implications of convergent procoagulant toxicity and differential antivenom efficacy in Australian elapid snake venoms</article-title><source>Toxicol. Lett.</source><year>2019</year><volume>316</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2019.08.014</pub-id><pub-id pub-id-type="pmid">31442586</pub-id>
</element-citation></ref><ref id="B84-toxins-17-00087"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
<name><surname>Woods</surname><given-names>D.</given-names></name>
<name><surname>Alley</surname><given-names>S.</given-names></name>
<name><surname>O&#x02019;Leary</surname><given-names>M.A.</given-names></name>
<name><surname>Seldon</surname><given-names>M.</given-names></name>
<name><surname>Lincz</surname><given-names>L.F.</given-names></name>
</person-group><article-title>Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom</article-title><source>Toxicon</source><year>2010</year><volume>56</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2010.03.013</pub-id><pub-id pub-id-type="pmid">20338189</pub-id>
</element-citation></ref><ref id="B85-toxins-17-00087"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Masci</surname><given-names>P.P.</given-names></name>
<name><surname>Whitaker</surname><given-names>A.N.</given-names></name>
<name><surname>de Jersey</surname><given-names>J.</given-names></name>
</person-group><article-title>Purification and characterization of a prothrombin activator from the venom of the Australian brown snake, <italic toggle="yes">Pseudonaja textilis textilis</italic></article-title><source>Biochem. Int.</source><year>1988</year><volume>17</volume><fpage>825</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">3075905</pub-id>
</element-citation></ref><ref id="B86-toxins-17-00087"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crawford</surname><given-names>A.M.</given-names></name>
<name><surname>Mills</surname><given-names>J.N.</given-names></name>
</person-group><article-title>An investigation, in vitro, of the actions of three Western Australian snakes on the blood coagulation of the dog, cat, horse and wallaby</article-title><source>Aust. Vet. J.</source><year>1985</year><volume>62</volume><fpage>185</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1111/j.1751-0813.1985.tb07291.x</pub-id><pub-id pub-id-type="pmid">4062725</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="toxins-17-00087-f001"><label>Figure 1</label><caption><p>Timeline of events following blood collection prior to final data generation.</p></caption><graphic xlink:href="toxins-17-00087-g001" position="float"/></fig><fig position="float" id="toxins-17-00087-f002"><label>Figure 2</label><caption><p>Thrombelastographic system using POC methodology and data generated. Blood is placed into cups with activators (e.g., tissue factor) &#x000b1; platelet inhibitors within a few minutes after collection from a patient or preclinical model. Activation of coagulation occurs immediately, with data collected over 15&#x02013;30 min. This radically reduces the &#x0201c;needle to activation time&#x0201d; of the analyses.</p></caption><graphic xlink:href="toxins-17-00087-g002" position="float"/></fig><fig position="float" id="toxins-17-00087-f003"><label>Figure 3</label><caption><p>North American rattlesnakes with some venom toxins and observed thrombelastographic outcomes. Red arrows indicate the consequent feature of coagulation affected by the enzyme or compound indicated or describes the thrombelastographic parameter affected. The dashed gray arrow indicates an interaction found in vitro [<xref rid="B27-toxins-17-00087" ref-type="bibr">27</xref>] but not in vivo [<xref rid="B36-toxins-17-00087" ref-type="bibr">36</xref>]. TMRTG&#x02014;time to the maximum rate of thrombus generation; MRTG (dynes/cm<sup>2</sup>/second)&#x02014;the maximum rate of thrombus generation, the maximum velocity of clot growth observed; TTG (dynes/cm<sup>2</sup>)&#x02014;total thrombus generation, the final viscoelastic resistance observed after clot formation. %TTG<sub>Plasma</sub> is calculated by dividing the TTG value of a platelet-inhibited sample by the corresponding TTG value of the whole-blood sample without platelet inhibition; %TTG<sub>Platelet</sub> is calculated as 100%&#x02013;%TTG<sub>Plasma</sub>.</p></caption><graphic xlink:href="toxins-17-00087-g003" position="float"/></fig><fig position="float" id="toxins-17-00087-f004"><label>Figure 4</label><caption><p>Venom source, components, and anticipated effects on thrombelastographic parameters. <italic toggle="yes">C. m. molossus</italic> is depicted at the top of the illustration; the enzymatic (green text) and nonenzymatic compounds (blue text) responsible for fibrinolysis and platelet aggregation found in the venom are subsequently displayed, and the expected increases or decreases in thrombelastographic parameters are depicted.</p></caption><graphic xlink:href="toxins-17-00087-g004" position="float"/></fig><fig position="float" id="toxins-17-00087-f005"><label>Figure 5</label><caption><p>Effects of <italic toggle="yes">C. m. molossus</italic> venom injection without or with platelet inactivation on whole blood. The left panels represent data generated from whole blood obtained from animals injected with venom (closed black circles). The right panels represent data obtained from whole blood from the same rabbits after platelet inhibition of the samples. Data are presented as mean &#x000b1; SD. TMRTG = time to maximum rate of thrombus generation (min); MRTG = maximum rate of thrombus generation (dynes/cm<sup>2</sup>/second); TTG = total thrombus generation (dynes/cm<sup>2</sup>). Time points are baseline before venom injection and one hour thereafter. * <italic toggle="yes">p</italic> &#x0003c; 0.01 vs. baseline.</p></caption><graphic xlink:href="toxins-17-00087-g005" position="float"/></fig><fig position="float" id="toxins-17-00087-f006"><label>Figure 6</label><caption><p>Effects of <italic toggle="yes">C. m. molossus</italic> venom on human plasmatic coagulation without or with inhibition by RuCl<sub>3</sub>. Control = plasma without additives; V = plasma with 24 &#x000b5;g/mL of venom; V + Ru = plasma with venom exposed to 100 &#x000b5;M RuCl<sub>3</sub> prior to addition of the venom into the plasma. Data are presented as mean &#x000b1; SD. * <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. Control, &#x02020; <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. V.</p></caption><graphic xlink:href="toxins-17-00087-g006" position="float"/></fig><table-wrap position="float" id="toxins-17-00087-t001"><object-id pub-id-type="pii">toxins-17-00087-t001_Table 1</object-id><label>Table 1</label><caption><p>Effect of ruthenium-based antivenom on a rabbit envenomed with <italic toggle="yes">C. m. molossus</italic> venom.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Baseline</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1 h</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Whole Blood</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TMRTG</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MRTG</td><td align="center" valign="middle" rowspan="1" colspan="1">13.7</td><td align="center" valign="middle" rowspan="1" colspan="1">13.7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TTG</td><td align="center" valign="middle" rowspan="1" colspan="1">978</td><td align="center" valign="middle" rowspan="1" colspan="1">987</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">%TTG<sub>Platelet</sub></td><td align="center" valign="middle" rowspan="1" colspan="1">87.3</td><td align="center" valign="middle" rowspan="1" colspan="1">87.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Platelet-Inhibited</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TMRTG</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MRTG</td><td align="center" valign="middle" rowspan="1" colspan="1">7.3</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TTG</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">127</td></tr></tbody></table></table-wrap><table-wrap position="float" id="toxins-17-00087-t002"><object-id pub-id-type="pii">toxins-17-00087-t002_Table 2</object-id><label>Table 2</label><caption><p>POC devices, data generated, and their manufacturers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">POC Device</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Data</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Manufacturer</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">PC100</td><td align="center" valign="middle" rowspan="1" colspan="1">Platelet Count</td><td align="center" valign="middle" rowspan="1" colspan="1">2M Engineering</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">qLabs FIB</td><td align="center" valign="middle" rowspan="1" colspan="1">Fibrinogen</td><td align="center" valign="middle" rowspan="1" colspan="1">Stago</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hemochron<sup>&#x000ae;</sup> Signature Elite</td><td align="center" valign="middle" rowspan="1" colspan="1">PT, aPTT</td><td align="center" valign="middle" rowspan="1" colspan="1">Werfen</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ROTEM sigma</td><td align="center" valign="middle" rowspan="1" colspan="1">Viscoelastic</td><td align="center" valign="middle" rowspan="1" colspan="1">Werfen</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TEG<sup>&#x000ae;</sup> 6s</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viscoelastic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Haemonetics Inc.</td></tr></tbody></table></table-wrap></floats-group></article>